Beneficial Effects of Resveratrol Against Colitis and Colorectal Cancer Mediated by the Host Microbiome, Epigenome, and Immune Response by Alrafas, Haider Rasheed Daham




Beneficial Effects of Resveratrol Against Colitis and
Colorectal Cancer Mediated by the Host
Microbiome, Epigenome, and Immune Response
Haider Rasheed Daham Alrafas
Follow this and additional works at: https://scholarcommons.sc.edu/etd
Part of the Biomedical Commons
This Open Access Dissertation is brought to you by Scholar Commons. It has been accepted for inclusion in Theses and Dissertations by an authorized
administrator of Scholar Commons. For more information, please contact dillarda@mailbox.sc.edu.
Recommended Citation
Alrafas, H.(2019). Beneficial Effects of Resveratrol Against Colitis and Colorectal Cancer Mediated by the Host Microbiome, Epigenome, and
Immune Response. (Doctoral dissertation). Retrieved from https://scholarcommons.sc.edu/etd/5206
 
 
BENEFICIAL EFFECTS OF RESVERATROL AGAINST COLITIS AND COLORECTAL 





Haider Rasheed Daham Alrafas 
 
Bachelor of Science 
University of Basrah, 2004 
 
Master of Science 




Submitted in Partial Fulfillment of the Requirements 
 




School of Medicine 
 






Mitzi Nagarkatti, Major Professor 
 
Prakash Nagarkatti, Committee Member  
 
Traci Testerman, Committee Member 
 
Susan K. Wood, Committee Member 
 
Sofia Lizarraga, Committee Member 
 
Cheryl L. Addy, Vice Provost and Dean of the Graduate School
 
ii 





 This work is dedicated to everyone who has helped me throughout my life, 
particularly my colleagues who shared this journey with me. I want to also dedicate this 




 I would like to thank my mentors, Dr. Mitzi Nagarkatti and Dr. Prakash 
Nagarkatti, for their support and leadership.  I want to thank my committee members, Dr. 
Traci Testerman, Dr. Susan K. Wood, and Dr. Sofia Lizarraga for their guidance and 
support. I would like to acknowledge Dr. Philip Brandon Busbee for his help and 
guidance as both a colleague and friend.  Thank you to Nicole Holt, Lee Ann Faulling, 
Tina Akers, and Margaret Whisenant for their service to our department.  I want to thank 
my fellow graduate students, postdocs, and faculty members from our laboratory for their 
wisdom and friendship. Thank you Dr. Esraah Al-Harris, Amira Mohammed, Kathryn 
Miranda, Dr. Hasan Al-Ghetaa , Osama Abdulla, Muthanna Sultan, William Becker and 
Zinah Al-Gheiz, Dr. Alexa Gandy, Dr. Marpe Bam, Wurood Neamah, and Nicholas 
Dopkins. I would like to thank my beloved country of Iraq for sending me to the United 
States and allowing me to complete my Ph.D. here.   
 Last, but most certainly not least, I want to thank and acknowledge my family in 
Iraq: my father, Rasheed; my mother; Batool; my brothers, Akra, Mohammad, and 
Moshtaq; my sister, Eqbal; and my wife, Marwa, and my kids Batool, Mostafa, and 
Sarah.  Most of the good I do and the person I am are in large part due to all of you in so 
many ways.  I thank you all for being there for me, through the good and bad, and I want 






 Resveratrol, a natural polyphenol compound found in red wine, the skins of 
grapes, and other plant products, has been used as a traditional medicine for thousands of 
years throughout human history, but current research has revealed this natural component 
is capable of modulating a variety of immunological, microbial, and epigenetic 
mechanisms to improve overall health and well-being of hosts that consume it. Colitis, an 
inflammatory bowel disease characterized by chronic inflammation in the colon and 
rectum, which has been associated with colon cancer.  This cancer incidence is rising in 
younger adults in the US.  Thus, newer approaches to prevent colitis and colon cancer are 
critical.  In this dissertation, data and evidence is presented which demonstrate that 
resveratrol, natural polyphenol can attenuate murine models of colitis and prevent colitis-
associated colon cancer.  In addition, in-depth mechanistic studies will provide evidence 
that resveratrol suppresses inflammation in the colon by regulating the host-gut 
microbiome, as well as inducing epigenetic changes via modulation of small noncoding 
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1.1 COLITIS AND COLITIS-ASSOCIATED COLON CANCER 
Inflammatory bowel diseases (IBDs), such as ulcerative colitis (UC) and Crohn’s 
disease (CD), are chronic digestive diseases defined by often uncontrollable 
inflammation along the gastrointestinal tract and colon (Singh et al., 2014b). The 
incidence and prevalence of these diseases has risen since 1980 in many parts of the 
world, particularly in the United States (Molodecky et al., 2012), and there is an alarming 
trend of these diseases increasing in the pediatric population (Ong et al., 2018; Sykora et 
al., 2018). Even more concerning is the link between colitis and an increased 
susceptibility to developing colorectal cancer (CRC) in animal models and the human 
patient population (Al Bakir et al., 2018; Foersch et al., 2012; Yang et al., 2018a). Colitis, 
as a form of IBD, has a complex etiology often attributed to many interrelated genetic, 
dietary, and other environmental factors (Hart, 2019; Mikhailov and Furner, 2009). 
Current conventional treatment options (e.g. steroids and immunosuppressive drugs) 
often have adverse side-effects, or in some cases, colitis patients are non-responsive to 
these conventional therapies (Antonelli et al., 2018). With increasing incidence, a link to 
development of CRC, and lack of effective treatment options, more studies are focusing 
on preventative measures to decrease colitis incidence. 
Recent advances in next-generation sequencing technology have shown that IBD 
may also result from alterations in the composition and function of gut microbiota, 
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referred to as dysbiosis. The gut microbiota also interact closely with dietary components 
to maintain normal immune system homeostasis in the gut.  Whether dietary supplements 
that are effective against colonic inflammation mediate their effects through modulation 
of gut microbiota is an area of investigation that is novel and highly significant. 
Colorectal cancer (CRC), which is characterized by tumor development in the 
large intestine, ranks as third among cancer incidences and fourth in cancer-related 
mortalities worldwide (Global Burden of Disease Cancer et al., 2015). Despite an overall 
decrease in CRC incidence in the United States among all race and ethnic groups due to 
standardized screening guidelines (Edwards et al., 2014), there has been a rise in 
prevalence of this disease among young adult patients which prompted the American 
Cancer Society to suggest the recommended age for CRC screening be lowered from 50 
to 45 (Pittman, 2018). Even with conventional chemotherapy options, which have major 
negative side-effects, patients often show chemo-resistance (Bose et al., 2011). It is for 
this reason, the emphasis has been on prevention of CRC development and regular 
screening to detect and cure at an early stage.  CRC development, is also associated with 
chronic inflammation and high levels of circulating inflammatory biomakers (Lopez et 
al., 2018; Song et al., 2018). Recent reports have shown that inflammation induced by 
certain types of diet and alterations in the microbiome is associated with increased risk of 
CRC development in men and women (Liu et al., 2018; Tabung et al., 2018). By the 
same token, diet and life styles that promote chronic inflammation in the gut is associated 
with dysregulation in the microbiome and development of colon tumorigenesis (Chen et 
al., 2017; Song et al., 2015).  Together, such studies suggest that use of preventative 
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agents against colonic inflammation, or colitis, could be beneficial in reducing the 
incidence of CRC.  
1.2 RESVERATROL 
Resveratrol (3,4,5-trihydroxy-trans-stilbene) is a natural polyphenol produced by 
several plants in response to injury or when the plant is under attack by pathogens such as 
bacteria or fungi (Singh et al., 2007). Resveratrol has been extensively studied for its 
therapeutic benefits against a wide array of diseases including cancer, cardiovascular, 
neurological and inflammatory diseases (Altamemi et al., 2014; Cui et al., 2010; de la 
Lastra and Villegas, 2005; Guan et al., 2012; Rieder et al., 2012; Singh et al., 2007; Singh 
et al., 2010; Wu et al., 2005). Resveratrol mediates these anti-inflammatory effects 
through multiple pathways (Rieder et al., 2012). For example, resveratrol has been shown 
to attenuate colitis by upregulating of silent mating type information regulation-1 
(SIRT1) in immune cells which is associated with the T regulatory cells (Treg) induction 
and activation of hypoxia-inducible Factor 1α (HIF-1α)/MTor signaling pathway (Singh 
et al., 2010; Yao et al., 2015). Resveratrol has also been shown to induce unique 
microRNA that trigger anti-inflammatory pathways as well as induce myeloid-derived 
suppressor cells (MDSCs) (Altamemi et al., 2014; Cui et al., 2010; Singh et al., 2010; 
Singh et al., 2012). While resveratrol has been shown to alter the gut microbiome in 
various disease models (Diaz-Gerevini et al., 2016; Etxeberria et al., 2015; Jung et al., 
2016; Tung et al., 2016), these studies have captured only an association between 
resveratrol-induced modulations in gut microbiota and the disease outcome.  Thus, 
conclusive evidence, such as through fecal transfer, is lacking to connect resveratrol-
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induced modulation in gut microbiota and its beneficial effects against disease 
pathogenesis. 
In addition, resveratrol has been shown to be a  promising preventive measure  to 
suppress chronic inflammation leading to tumor development (Busbee et al., 2013). 
Resveratrol has already been shown by our lab, as well as others, to possess a myriad of 
anti-cancer effects, including those related to CRC. This natural compound has been 
shown to be effective at preventing the proliferation and survival of human CRC cells as 
well decrease CRC disease severity and tumor development in relevant animal CRC 
models (Busbee et al., 2013; Elshaer et al., 2018; Hofseth et al., 2010). Some of the 
mechanisms by which resveratrol has been shown to prevent colon cancer cell 
proliferation and invasion metastasis include regulation of key cellular signaling 
pathways such as NF-Κb-dependent cellular processes (Buhrmann et al., 2017), 
PI3K/Akt signaling (Zeng et al., 2017), modulation of histones and sirtuins (San 
Hipolito-Luengo et al., 2017), inhibition of cyclooxygenase-2 (Cox-2) expression (Gong 
et al., 2017), and alterations in gene-regulating microRNAs (miR) (Yang et al., 2015). 
Previous reports from our lab have shown that resveratrol is able to alter expression of 
certain miRs (miR-101b and miR-455) that target inflammatory mediators such as 
interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-α), and COX-2 in the dextran 
sodium sulfate (DSS)-induced colitis-associated tumorigenesis Apc(Min/+) mouse model 
(Altamemi et al., 2014). In addition, in the AOM/DSS CRC model, we have shown that 
resveratrol downregulates inflammatory stress markers such as p53 to modulate the T cell 
response (Cui et al., 2010). However, while the regulation of these host-derived cellular 
mechanisms play an important role in resveratrol-mediated CRC treatment, recent 
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research has shown the gut microbiome is also a key player in both CRC disease 
development and progression (Chen, 2018).  Nonetheless, whether the ability of 
resveratrol to suppress CRC is related to its action on gut microbiota remains a possibility 
that needs to be explored.  
1.3 THE GUT MICROBIOME 
The gut microbiome, a diverse ecosystem consisting of gut commensals including 
bacteria and fungi, has been shown to have a great impact on human health and disease, 
particularly in CRC (Jobin, 2017; Rezasoltani et al., 2017; Zou et al., 2018). For example, 
patients diagnosed with CRC were found to have distinct microbiome profiles compared 
to healthy controls, and this microbial signature was found to be altered after treatment 
with probiotics (Hibberd et al., 2017). Interestingly, after oral administration of 
antibiotics to deplete the gut microbiome, tumor burden was decreased in a CRC murine 
model, but this effect was negated in Rag-deficient mice that lacked mature T cells and B 
cells (Sethi et al., 2018). This study highlights the importance of the interplay between 
the host immune defense the microbiome. While resveratrol has been shown to modulate 
the host immune response to promote anti-inflammation as previously discussed and has 
been shown to alter the microbiome in other disease models (Chen et al., 2016; Kim et 
al., 2018; Qiao et al., 2014; Zhao et al., 2017), there currently are no reports determining 
if resveratrol-mediated alterations in the gut microbiome can influence the immune 
response to protect against CRC development caused by chronic colitis.  
1.4 MICRORNA  
microRNA (miRNA or miR) are small 18-25 nucleotide non-coding RNAs that 
regulate the expression of several protein-encoding genes post-transcriptionally by either 
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inhibiting translation of targeted-miR or leading to the degradation of certain targeted-
mRNA transcripts, and even though they make up only 3% of the human genome, it has 
been estimated that these non-coding RNAs regulate around 90% of genes  (Guo et al., 
2018). Canonical miR biogenesis begins in the nucleus when miR genes are transcribed 
by either RNA polymerase II or III to produce primary miRNA transcripts (pri-miRNAs).  
While still in the nucleus, pri-miRNA is cleaved by a class 2 RNAase III enzyme, called 
Drosha, to create a 60-70 nucleotide hairpin structured precursor (pre-miRNA).  The pre-
RNA is then shuttled from the nucleus to the cytoplasm by Exportin 5 (Exp5), where it is 
released by Exp5 when GTP on the Exp5-associated Ran cofactor is converted to GDP.   
While in the cytoplasm, another RNase called dicer cleaves pre-miRNA into a duplex 
intermediate.  The duplex intermediate is bound to an Argonaute (AGO) protein to form a 
AGO:mature miRNA strand complex, where one strand of the intermediate is discarded 
(Catalanotto et al., 2016).  
miRs were found to be important in both the development and progression of 
colitis, particularly in terms of regulating inflammation, serving as disease biomarkers, 
and responding to therapies (Feng et al., 2018; Lopetuso et al., 2018; Minacapelli et al., 
2019; Morilla et al., 2018; Schonauen et al., 2018; Singh et al., 2014a). The importance 
of miRs in regulating colitis was highlighted in our previous report showing that 
deficiency in only one miR (miR-155) was able to protect mice from developing severe 
colitis symptoms by a reduction in the inflammatory T helper (Th) type responses (Singh 





1.5 PROBLEM AND HYPOTHESIS 
IBD patients represent a high risk group for developing colitis-associated CRC, 
and these diseases, which currently has no cure, result in an overall decrease in quality of 
life and an increase in health care costs. There is need to seek out new and novel 
treatments to combat the inflammatory response initiated by colitis and colitis-associated 
colorectal cancer.  Therefore, we examined how the use of natural product, resveratrol, 
could prevent colitis-induced T cell activation and inflammation which could lead to 
colorectal cancer.  Based on recent findings that resveratrol has anti-inflammatory and 
anti-microbial properties, we hypothesized that resveratrol would be a novel treatment for 
colitis and colitis-associated CRC in relevant mouse models through alterations in gut 




RESVERATROL MODULATES THE GUT MICROBIOTA TO PREVENT MURINE 
COLITIS DEVELOPMENT THROUGH INDUCTION OF TREGS AND SUPPRESSION OF 
TH17 CELLS 
2.1 ABSTRACT 
Inflammatory diseases of the gastrointestinal tract are often associated with 
microbial dysbiosis. Thus, dietary interactions with intestinal microbiota, to maintain 
homeostasis, play a crucial role in regulation of clinical disorders such as colitis. In the 
current study, we investigated if resveratrol, a polyphenol found in a variety of foods and 
beverages, would reverse microbial dysbiosis induced during colitis. Administration of 
resveratrol attenuated colonic inflammation and clinical symptoms in the murine model 
of TNBS-induced colitis. Resveratrol treatment in mice with colitis led to an increase in 
CD4+FOXP3+ and CD4+IL-10+ T cells, and a decrease in CD4+IFN-γ+ and CD4+IL-
17+ T cells. 16S rRNA gene sequencing to investigate alterations in the gut microbiota 
revealed that TNBS caused significant dybiosis, which was reversed following 
resveratrol treatment. Analysis of cecal flush revealed that TNBS administration led to an 
increase in species such as Bacteroides acidifaciens, but decrease in species such as 
Ruminococcus gnavus and Akkermansia mucinphilia, as well as a decrease in SCFA i-
butyric acid. However, resveratrol treatment restored the gut bacteria back to homeostatic 
levels, and increased production of i-butyric acid. Fecal transfer experiments confirmed 
the protective role of resveratrol-induced microbiota against colitis inasmuch as such 
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recipient mice were more resistant to TNBS-colitis and exhibited polarization towards 
CD4+FOXP3+ T cells and decreases in CD4+IFN-γ+ and CD4+IL-17+ T cells. 
Collectively, these data demonstrate that resveratrol-mediated attenuation of colitis 
results from reversal of microbial dysbiosis induced during colitis and such microbiota 
protect the host from colonic inflammation by inducing Tregs while suppressing 
inflammatory Th1/Th17 cells. 
2.2 INTRODUCTION 
 Here, we demonstrate that during colitis, microbial dysbiosis takes place in the 
host, which leads to the activation and differentiation of inflammatory effector T cells 
and inhibition of Tregs. However, upon treatment with resveratrol, these changes are 
reversed, leading to the development of an anti-inflammatory Treg response. More 
importantly, we conclusively prove that this mechanism is driven by resveratrol-mediated 
alterations in the gut microbiome by performing fecal transplant experiments, thereby not 
only reinforcing the notion that resveratrol is a potential therapeutic against colitis, but 
also providing a key mechanism through which resveratrol mediates its effects. 
2.3 MATERIALS AND METHODS 
Animals. Female BALB/c mice (aged 6-8 weeks) were purchased from the 
Jackson Laboratories (Bar Harbor, ME). All mice were housed at the AAALAC-
accredited animal facility at the University of South Carolina, School of Medicine 
(Columbia, SC).  All procedures were performed according to NIH guidelines under 
protocols approved by the Institutional Animal Care and Use Committee. 
Effects of resveratrol on colitis in mice.  To test the efficacy of treatment with 
resveratrol in an in vivo TNBS-induced colitis mouse model, we used TNBS, purchased 
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from Sigma-Aldrich (St. Louis, MO). After lightly anesthetizing the mice with controlled 
isoflurane vaporizer chamber (5% isoflurane with 75% CO2/25% O2), TNBS was 
administered  intrarectally one time  into female BALB/c mice at a dose of 1 mg 
dissolved 0.1 ml of 50% ethanol using a 38 mm catheter, as previously reported (Elson et 
al., 1996).  For treatment groups resveratrol, purchased from Sigma-Aldrich (St. Louis, 
MO), was administered orally using a 30 mm oral gavage needle at 100 mg/kg, a dose 
established in our previous studies (Singh et al., 2010), in a total volume of 100µl in 
appropriate vehicle of 1% carboxymethyl cellulose (CMC).  Resveratrol was given 24 
hours prior to TNBS injection and given daily this way until completion of the 
experiment (5 days). Two control groups were used for this study. One control group 
only received appropriate vehicle (CMC), while the other control group received 100 
mg/kg resveratrol dissolved in CMC vehicle. Neither of these control groups received 
injection of TNBS. The evaluation of colitis clinical signs was done by measuring the 
weight of mice in all groups daily and performing colonoscopy every other day after 
TNBS-colitis induction. Colonoscopy scores were determined using a scoring system 
previously published (Kodani et al., 2013). In addition, blood was collected prior to 
experimental endpoint and serum samples were separated and stored at -20°C for colitis-
associated biomarker detection. All experimental mice studied were also given intrarectal 
injections of 50% ethanol to ensure changes in the gut were due to either TNBS or 
treatment and not attributed to alterations by ethanol. Resveratrol efficacy was also tested 
in the dextran sodium sulfate (DSS) model of colitis. DSS (3%) was used to induce 
disease as previously reported (Cui et al., 2010), and treatment groups (DSS+Resveratrol) 
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were given oral administration of 100 mg/kg of the compound daily throughout the 14-
day experiment. 
Histology analysis. Animals were euthanized 5 days after injection of TNBS 
using the drop jar method containing 5% isoflurane (260 mL in 1 L drop jar) for overdose 
inhalation, and the proximal portion of colons were excised and cleaned by saline 
flushing. The length of colon was measured before fixing the excised tissue with 4% 
paraformaldehyde. Colon pieces were embedded in paraffin, cut into 5µm sections, 
deparaffinized in xylene, serially diluted in decreasing concentrations of ethanol, and 
stained with hematoxylin-eosin (H&E) for histopathological examination and Periodic 
Acid Schiff (PAS) staining to assess mucosal mucin production and presence of goblet 
cells. Histological scoring of colon sections was determined using previously published 
criteria (Akgun et al., 2005). 
Serum evaluation by enzyme-linked immunoabsorbant assay (ELISA). Acute 
phase serum amyloid A (SAA), Lipocalin-2 (Lcn2), myeloid peroxidase (MPO), and 
interleukin-10 (IL-10) levels in the serum were measured by using enzyme-linked 
immunosorbent assay (ELISA) kits. SAA ELISA kit was purchased from Abcam 
(Cambridge, United Kingdom), Lcn-2 ELISA kit was purchased from Thermo-Scientific 
(Waltham, Massachusetts, USA), MPO ELISA kit was acquired from LifeSpan 
BioSciences (Seattle, WA) and the IL-10 Luminex ELISA kit was purchased from 
Biolegend (San Diego, CA). All kits were used in accordance with the respective 
manufacturer’s protocol. 
 Flow cytometry staining and analysis. Cells from mesenteric lymph nodes were 
isolated and the red blood cells were lysed using lysis buffer (Sigma, St Louis, MO). Cell 
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suspensions were filtered using sterile 70 micron filters (Sigma, St Louis, MO). Four-
color flow cytometric analysis was performed following blocking with Fc receptor. All 
cells were washed with FACS staining buffer (PBS with 1% fetal bovine serum), then 
stained with FITC-labeled anti-CD3, PE-labeled anti-CD8 and PE-CY7-labeled anti-CD4 
at manufacturer suggested concentrations (Biolegend, San Diego, CA). For intracellular 
staining, cells previously stained for membrane proteins were fixed and permeabilized 
using a Fix/Perm kit (Biolegend, San Diego, CA). Cells were stained with PE-Cy7-
labeled CD4, PE-labeled Foxp3, FITC-labeled IL10, PE-labeled IFN-γ, and FITC-labeled 
IL-17 (Biolegend, San Diego, CA). Flow cytometry data was analyzed using a CXP 
FC500 flow cytometer (Beckman Coulter, Brea, CA) and the gating strategy for shown 
represented plots is shown in Figure 2.1. 
Genomic DNA extraction and 16S rRNA gene sequencing. Colonic flushes 
were used for pyrosequencing analysis to characterize the gut microbiome composition. 
The extraction of genomic DNA from colonic flushes was carried out using the QIAamp 
DNA Stool Mini Kit (Qiagen, Hilden, Germany) according to the manufacture's 
instruction. The DNA concentration were determined using a NanoDrop ND-1000 
spectrophotometer and stored at −20°C until further processing. Amplification of the 16S 
rRNA V3-V4 hypervariable gene region was carried out using the 16S V3 314F forward 
(5′TCGTCGGCAGCGTCAGATGTGTATAAGAGACAGCCTACGGGNGGCWGCAG
3′) and V4 805R reverse primers 
(5′GTCTCGTGGGCTCGGAGATGTGTATAAGAGACAGGACTACHVGGGTATCT
AATCC3′) with added Illumina adapter overhang nucleotide sequences. The PCR 
conditions used  were as follows: 3 minutes (min) at 95°C, follow by 25 cycles of 30 
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seconds (s) at 95°C, 30 s at 55°C and 30 s at 72°C, and a final extension at 72°C for 5 
min. Each reaction mixture (25 μl) contained 50 ng of genomic DNA, 0.5 μl of amplicon 
PCR forward primer (0.2 μM), 0.5 μl of amplicon PCR reverse primer (0.2 μM) and 12.5 
μl of 2× KAPA Hifi Hot Start Ready Mix. Each reaction was cleaned up with Agencourt 
AMPure XP beads (Beckman Coulter, Indianapolis, IN). Attachment of dual indices and 
Illumina sequencing adapters was performed using 5 μl of amplicon PCR DNA product, 
5 μl of Illumina Nextera XT Index Primer 1 (N7xx), 5 μl of Nextera XT Index Primer 2 
(S5xx), 25 μl of 2× KAPA HiFi Hot Start Ready Mix, and 10 μl of PCR-grade water in 
this case. Amplification was carried out under the following conditions: 3 min at 95°C, 
followed by 8 cycles of 30 s at 95°C, 30 s at 55°C, and 30 s at 72°C, and a final extension 
at 75°C for 5 min. Constructed 16S rRNA gene libraries were purified with Agencourt 
AMPure XP beads and quantified with Quant-iT PicoGreen dsDNA Assay kit (Thermo 
Fisher Scientific, Waltham, MA). Library quality control and average size distribution 
were determined with the Agilent Technologies 2100 Bioanalyzer (Agilent, Santa Clara, 
CA). Libraries were normalized and pooled to 40 nM based on quantified values. Pooled 
samples were denatured and diluted to a final concentration of 6 pM with a 30% PhiX 
(Illumina, San Diego, CA) control. Amplicons were subject to pyrosequencing using the 
MiSeq Reagent Kit V3 in the Illumina MiSeq System. 
Microbial 16S rRNA gene analysis of sequencing data. The online 16S analysis 
software from National Institute of Health (NIH, Baltimore, MD), known as Nephele 
(https://nephele.niaid.nih.gov/), was used to analyze sequencing data collection from the 
Illumina MiSeq platform. FASTQ sequences were uploaded to Nephele and the 16S 
metagenomics application was performed. Groups of related DNA sequences were 
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assigned to operational taxonomic units (OTUs), and Nephele-generated output files were 
analyzed to determine gut microbial composition. Linear Discrimination Analysis Effect 
Size (LEfSe) was performed on Nephele-generated OTU output data in order to 
determine microbial biomarkers among experimental groups as previously described 
(Segata et al., 2011). 
Quantitative Real-Time PCR. For validation of bacteria identified by 16S rRNA 
gene analysis, qRT-PCR was used. DNA was extracted from cecal samples using the 
QIAamp DNA Stool Mini Kit (Qiagen, Hilden, Germany). Samples were analyzed by 
PCR using primers designed to amplify bacterial 16S rRNA genes. For quantification of 
Ruminococcus gnavus (5′AGAGGGATGTCAAGACCAGGTA, 
3′TACTAGGTGTCGGGTGGAAAAG), Akkermansia muciniphila 
(5′GTATCTAATCCCTTTCGCTCCC, 3′GACTAGAGTAATGGAGGGGGAA), and 
Bacteroides acidifaciens (5′GTATGGGATGGGGATGCGTT, 
3′CTGCCTCCCGTAGAGTTTGG) the StepOnePlus Real-Time PCR system was used. 
Fold changes from PCR analysis were obtained by using the delta-delta CT method with 
comparison to the control group (Vehicle). 
SCFAs identification and quantification. Colonic flushes were collected 
immediately after euthanasia by excising colon tissues and flushing them with PBS. 
Samples were collected into in 2 ml Eppendorf tubes under anaerobic conditions. 
Samples collected were immediately frozen at −80 °C for future analysis. Samples were 
analyzed for SCFA concentrations using 2-Ethylbutyric acid as internal standard as 
previously described (Chitrala et al., 2017). Briefly, the cecal samples (100 mg) were 
suspended and homogenized in water. After centrifugation for 10 min at 12,000 rpm, the 
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supernatant was acidified by addition 25% metaphosphoric acid. The internal standard 
was added into the supernatant. SCFAs were identified and quantified using a HP 5890 
gas chromatograph configured with flame-ionization detectors (GC-FID) and SCFAs 
were identified using control standard compounds purchased from Sigma-Aldrich. 
Fecal transfer experiment. Fecal material  from TNBS+Vehicle or 
TNBS+Resveratrol mice was collected 48 hours after the last day of oral gavage 
treatment in the experimental model (day 5) from colonic flushes under anaerobic 
conditions (using anerobic glove box chamber) prior to inoculation into recipient mice in 
200 μl of PBS. Fecal material was collected 48 hours after the last treatment to ensure 
that resveratrol had been absorbed in the tissues and eliminated from the feces prior to 
collection, as studies have shown this natural compound is rapidly absorbed and 
eliminated after consumption (Busbee et al., 2013).  Before the fecal transfer, recipient 
mice (6 weeks old) were treated with streptomycin and penicillin to deplete endogenous 
gut microbiota. Penicillin (1g/L) and streptomycin (1g/L) were dissolved in sterile water 
and 100 µl were fed into mice by oral gavage once a day for four consecutive weeks, as 
previously described (Khosravi et al., 2014). Depletion of microbiota was validated by 
PCR analysis using 16S rRNA gene Eubacteria primer (5′ATTACCGCGGCTGCTGGC, 
3′ACTCCTACGGGAGGCAGCAGT). Colitis induction was performed as previously 
described. Briefly, on the last day of antibiotic treatment, prior to disease induction, 
recipient mice were given feces (5g/L stocks from disease and treated groups) by oral 
gavage (100 µl) for 5 days. Body weights were measured daily and colonoscopy was 
performed every other day. At the end of experiment, the mice were sacrificed and colon 
tissues were taken for histopathology analysis by staining with H&E and PAS as 
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described already. Mesenteric lymph nodes were taken and T cell phenotyping was 
performed using flow cytometry as described above. 
Statistical Analysis.  GraphPad Prism software (San Diego, CA) was used for all 
statistical analysis.  For the in vivo mouse experiments, groups of 5-10 mice were used 
per experimental group.  For in vitro assays, all experiments were performed in triplicate.  
For statistical differences, one-way ANOVA was used for each experiment, and Tukey’s 
post-hoc test was performed to analyze differences between groups, unless otherwise 
indicated.  A p value of at least ≤ 0.05 was used to determine statistical significance. 
2.4 RESULTS 
Resveratrol attenuates TNBS-induced colitis 
In the current study, we tested the ability of  resveratrol to attenuate a well-
characterized TNBS-mediated murine model of colitis (Kim and Berstad, 1992). We used 
4 groups of mice:  Vehicle alone, resveratrol alone, TNBS+Vehicle, and 
TNBS+Resveratrol.  TNBS administration caused colitis with significant decrease in 
body weight (~20%) when compared to Vehicle- or resveratrol-treated only groups, as 
depicted in Figure 2.2A. However, in the TNBS+Resveratrol group, the weight loss was 
significantly reversed (~8%).  Additionally, the TNBS+Vehicle group showed ~60% 
survival, while TNBS+Resveratrol group showed 100% survival (Figure 2.2B). Colitis-
induction caused an overall decrease in the colon length in TNBS+Vehicle groups 
compared to those treated with either Vehicle or Resveratrol alone, as shown in Figure 
2.2C-D. However, TNBS+Resveratrol groups showed a significant increase in colon 
length when compared with the disease group (TNBS+Vehicle). Colitis is also 
characterized by large productions of inflammatory biomarkers such as SAA, Lcn2, and 
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increased MPO activity, which are often used in the diagnosis of the severity of colitis 
(Martinez-Moya et al., 2012; Singh et al., 2012). The level of these biomarkers were 
significantly elevated in the TNBS+Vehicle group (Figure 2.2E-G), but 
TNBS+Resveratrol showed significant decreases in the levels of all those inflammatory 
biomarkers, collectively showing that resveratrol was able to ameliorate the colonic 
inflammatory response induced by TNBS. Similar results were obtained in DSS-induced 
colitis model with the current resveratrol treatment regimen. Oral administration of 
resveratrol prevented DSS colitis-induced weight loss (Figure 2.3A) and colon shortening 
(Figure 2.3B-C).    
Colonoscopic examination at 3 different time points (days 0, 3, and 5) during the 
experiment gave a clear picture of the development of colitis-associated lesions and tissue 
sloughing after TNBS injection (TNBS+Vehicle), but TNBS+Resveratrol mice showed 
marked decrease in tissue disruption (Figure 2.2H-I). Histological examination of 
formalin-fixed colon tissues stained with H&E was also performed (Figure 2.4A), which 
showed a significant amount of cellular infiltration and loss of mucosal architecture in the 
TNBS+Vehicle group compared to naive mice treated with either just Vehicle or 
resveratrol alone.  In contrast, TNBS+Resveratrol mice showed marked reduction in 
cellular infiltration, resembling the control groups. We also performed PAS staining on 
fixed colon tissue to determine normal arrangement and distribution of mucin and goblet 
cells within the colon mucosa. Mice challenged with TNBS showed high reduction in the 
number of goblet cells and mucin thickness, which was greatly returned to normal levels 
and size of mucin thickness in colons excised from TNBS+Resveratrol mice, similarly to 
naïve mice treated with Vehicle or resveratrol only (Figure 2.4B). Histological scores of 
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colons from TNBS mice treated with resveratrol (TNBS+Resveratrol) showed a 
significant decrease in disease parameters compared to TNBS+Vehicle mice, which had 
much higher scores than the controls groups (Figure 2.4C). These data suggested that 
resveratrol prevents the colonic tissue damage induced by TNBS, which includes loss of 
the naturally-occurring protective mucous layer.  
Resveratrol treatment reduces inflammatory T cell subsets and increases 
anti-inflammatory Tregs 
 In order to examine the T cell subsets during disease and treatment states, 
we isolated cells from the mesenteric lymph node of all groups and phenotyped these 
cells using flow cytometry. First, we looked at expression of the general T cell marker 
(CD3) which showed a significant increase in the percentage in TNBS+RES mice, while 
TNBS+Resveratrol treatment led to a marked decrease (Figure 2.5A). We next looked at 
both T helper (CD4+) and cytotoxic (CD8+) T cell subset populations and showed 
significant increases in both CD4+ and CD8+ T cells in TNBS+Vehicle mice compared 
with those that were treated with Vehicle or resveratrol alone (Figure 2.5B), but this was 
effectively reduced in TNBS+Resveratrol groups.  We then performed 
intracellular/intranuclear staining to identify the effect of resveratrol on specific CD4+ T 
cells subsets which include inflammatory IFNγ- and IL17-producing CD4+ T cells, in 
addition to anti-inflammatory CD4+FOXP3+ and CD4+IL10+ populations. The data 
showed a significant increase in percentages of both anti-inflammatory CD4+FOXP3+ 
and CD4+IL10+ cells population in the TNBS+Resveratrol group when compared 
TNBS+Vehicle, and this increase in CD4+FOXP3+ populations were also observed in 
naïve mice treated with resveratrol (Figure 2.5C-D). In contrast, intracellular staining for 
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CD4+IFNγ+ and CD4+IL17+ showed significant increases in both percentage and absolute 
cell number in TNBS+Vehicle mice, while those in the TNBS+Resveratrol had a reversal 
in this effect (Figure 2.5E-F). Absolute cell numbers of T cells and T cell subsets in the 
MLN confirmed these findings (Figure 2.5G).  Collectively, these data showed that 
resveratrol treatment reduces the inflammatory T cell response during TNBS-induced 
colitis, while promoting the production of anti-inflammatory T cell subsets, mainly Tregs 
and IL-10-producing CD4+ cells. This increase in Tregs was also observed in naïve mice 
that were treated only with resveratrol alone. 
Alterations in gut microbiota and SCFA composition in colitis-induced mice 
treated with resveratrol  
 Next, we analyzed the gut microbiota from the all experimental groups to 
determine whether or not resveratrol altered the gut microbial composition during colitis. 
From colonic flushes, we isolated genomic DNA and performed 16S rRNA gene 
sequencing, analyzing the sequenced reads with the NIH-based Nephele online analysis 
tool. Nephele analysis output showed that the alpha diversity, represented as chao1, in 
naïve mice treated with resveratrol had the most diverse gut microbial compositions when 
to the other groups (Figure 2.6A). In terms of beta diversity, depicted as a PCA plot, 
samples clustered within their respective groups, with TNBS+Vehicle samples showing 
more dissimilarity compared to Vehicle-treated, or those groups treated with resveratrol 
(Resveratrol or TNBS+Resveratrol) (Figure 2.6B). 16s rRNA gene sequencing analysis 
from Nephele allowed sample reads to be classified into OTUs from phylum to the 
species level, and output data up to the genus level is summarized in Figures 2.7-2.9. In 
order to determine the most divergent and potential microbial biomarkers within 
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experimental groups, LeFSe analysis was performed with comparisons of TNBS+Vehicle 
vs TNBS+Resveratrol (Figure 2.6C-D). The results showed that TNBS+Vehicle mice had 
increased abundance of Bacteroides acidifaciens compared to the other groups (Figure 
2.6E), while naïve or TNBS-induced colitis mice treated with resveratrol had enrichment 
of bacteria belonging to the genus Ruminococcus (Figure 2.6C).  At the species level, 
Ruminococcus gnavus and Akkermansia muciniphila showed a significant increase in 
TNBS+Resveratrol groups when compared to TNBS+Vehicle groups (Figure 2.6F-G). It 
is interesting to note that mice treated with resveratrol alone also showed increases in 
Ruminococcus gnavus (Figure 2.6F).  In order to validate our sequencing results at the 
species level, we performed PCR using bacterial species-specific primers. As shown in 
Figure 2.6H-J, Bacteroides acidifaciens was increased in the TNBS+Vehicle group 
compared to naïve mice treated with Vehicle or resveratrol only, but this species was 
reduced in the TNBS+Resveratrol group (Figure 2.6H). In addition, Ruminococcus 
gnavus and Akkermansia muciphila species showed significant increases in abundance in 
groups treated with resveratrol (Resveratrol or TNBS+Resveratrol) when compared to 
those treated with only vehicle (Vehicle or TNBS+Vehicle) (Figure 2.6I-J). 
 Lastly, we measured the SCFA production in response to these changes in 
the gut microbiome composition (Figure 2.10).  The data showed that acetic acid and i-
butyric acid concentrations were significantly reduced in the TNBS+Vehicle groups 
when compared to Vehicle, while naïve mice treated with resveratrol and TNBS+RES 
groups showed significant increases in these SCFAs (Figure 2.10A, 2.10C). However, 
propionic acid, n-butyric acid, i-valeric acid, n-valeric acid, and n-copric acid showed no 
significant changes among the various groups (Figure 2.10B, 2.10D-F). Together, these 
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data suggested that treatment with resveratrol, particularly in colitis induced conditions, 
significantly altered both the gut microbiome composition and SCFA production. 
Fecal transfer from resveratrol-treated groups attenuates TNBS-induced 
colitis and alters the immune response 
 In order to determine whether or not resveratrol-induced alterations in the 
gut microbiome contributes to the altered immune response in colitis, we performed fecal 
transfer experiments following treatment of mice with antibiotics to deplete the existing 
gut microbiota. While there were no significant differences observed in body weight of 
mice in the wild-type and antibiotic-treated mice (Figure 2.11A), PCR for the universal 
Eubacteria 16S rRNA gene confirmed that the microbiome was depleted in antibiotic-
treated mice prior to inoculation with fecal material (Figure 2.11B-C). TNBS-exposed 
mice were inoculated with either feces from TNBS-treated mice ((FT) TNBS+Vehicle), 
or inoculated with feces from TNBS+Resveratrol-treated mice ((FT) TNBS+Resveratrol). 
(FT) TNBS+Vehicle mice showed a gradual decrease in body weight until the 
termination of the experiment (Figure 2.11D). However, (FT) TNBS+Resveratrol mice 
showed resistance to loss of body weight.  TNBS-induced colitis mice transferred with 
feces from TNBS+Vehicle also had shorter colons when compared those receiving fecal 
transfers from TNBS+Resveratrol-treated mice (Figure 2.11E-F). Looking at colitis-
associated inflammatory biomarkers such as SAA, Lcn2, and MPO, we found that the 
(FT) TNBS+Resveratrol group had significantly lower levels of these inflammatory 
biomarkers compared to the (FT) TNBS+Vehicle group (Figure 2.11G-I). In addition, 
colonoscopy examination showed increased ulceration and sloughing in portions of the 
colon in (FT) TNBS+Vehicle mice, while (FT) TNBS+Resveratrol groups showed 
 
22 
reduced presence of colon tissue destruction (Figure 2.11J, top panel). Colonoscopy and 
histological examination of formalin-fixed colon tissues stained with H&E also showed 
that (FT) TNBS+Resveratrol mice showed no signs of cellular infiltration and tissue 
destruction, while (FT) TNBS+Vehicle mice had these colitis-associated observations 
(Figure 2.11J-K). 
 Lastly, we performed T cell CD4+ phenotyping of the mesenteric lymph 
nodes in these fecal transfer experiments.  The data showed that there was significant 
increases in CD4+FOXP3+ Tregs (Figure 2.11L), though not in CD4+IL10+ (Figure 
2.11M), populations in the (FT) TNBS+Resveratrol group compared to (FT) 
TNBS+Vehicle, and the inflammatory Th1 (CD4+IFNγ+) and Th17 (CD4+IL17+) 
numbers were significantly reduced in these mice as well (Figure 2.11N-O). In order to 
confirm that relevant species were in fact altered during the FT experiments, PCR 
validation was performed on colonic flushes from these experimental FT groups. PCR 
validation showed that mice (FT) TNBS+Resveratrol mice did have increased levels of 
Akkermansia muciniphila (Figure 2.11P) and Ruminococcus gnavus (Figure 2.11Q) when 
compared to (FT) TNBS+Vehicle mice. In addition, there was significantly lower levels 
of Bacteroides acidifaciens in (FT) TNBS+Resveratrol groups compared to (FT) 
TNBS+Vehicle (Figure 2.11R), confirming that prominent species from the sequencing 
data were transferred successfully. Together, the fecal transfer experiments demonstrated 
that microbiota from (FT) TNBS+Resveratrol groups provide significant protection from 




Resversatrol is a potent anti-inflammatory agent.  Studies from our lab and 
elsewhere have shown the ability resveratrol to reduce the symptoms associated with 
colitis, in different murine models (Martin et al., 2006; Singh et al., 2012; Wagnerova et 
al., 2017; Yao et al., 2015; Youn et al., 2009), as well as in human patient populations 
(Samsami-Kor et al., 2015). Resveratrol is known to act through multiple pathways.  In 
our previous reports, we were able to reveal some of the mechanisms that made this 
natural compound such a successful treatment. For example, in the genetic IL-10-/- 
model of colitis, we showed that resveratrol treatment was able to induce 
immunosuppressive MDSCs that led to a reduction in clinical parameters in addition to 
the reduction in CXCR3 expressing T cells (Singh et al., 2012). The ability of resveratrol 
to induce these anti-inflammatory MDSCs has been shown in our lab in other disease 
models (Altamemi et al., 2014; Guan et al., 2012; Rieder et al., 2012), and been 
confirmed by others as well (Chen et al., 2015a; Hong et al., 2017). Other studies have 
shown that the beneficial effects of resveratrol against colitis can be attributed to other 
mechanisms, such as targeting sphingosine kinase 1 (SphK1) and apoptosis, restoring 
nitric oxide levels, reducing neutrophil infiltration, inhibiting nuclear factor-kappaB 
activation, acting as an anti-oxidant, as well as inhibiting adhesion molecules (Abdallah 
and Ismael, 2011; Abdin, 2013; Yao et al., 2011). Resveratrol is also well-known to be a 
ligand for the aryl hydrocarbon receptor (AhR), and our lab and others have shown this 
natural compound’s ability to shift T cell differentiation from Th17 to Tregs, which is 
dependent on this receptor-ligand interaction (Singh et al., 2007; Wang et al., 2013). 
Classically, Th1 and Th2 cells were thought to characterize Crohn’s disease and 
ulcerative colitis respectively, however, Th17 cells are now known to play an important 
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role in gut immunity and inflammation, particularly in regards to IBDs such as colitis 
(Ueno et al., 2018). Genome-wide association (GWAS) studies in IBD patients found that 
IL-17 regulating genes are greatly altered in the disease state, thus suggesting the 
importance of this factor in IBD such as colitis (Ueno et al., 2018). In fact, both animal 
models of colitis and human IBD patients are characterized by increased presence and 
development of Th17 cells at sites of inflammation (Galvez, 2014; Jiang et al., 2014; Lee 
et al., 2012). Th17 plasticity towards inflammatory (IFN-γ-producing Th1) or anti-
inflammatory (Treg) phenotypes make it a very unique cell population involved in 
intestinal homeostasis (Galvez, 2014). Interestingly, recent research has shown that Th17 
cells are greatly influenced by the microenvironment such as the microbiome and 
microbial-derived byproducts (Ueno et al., 2018). 
More recent studies have shown that resveratrol may protect against many clinical 
disorders by modulating the gut microbiota (Bird et al., 2017; Chen et al., 2016; Sung et 
al., 2017).  However, such studies did not perform fecal transfer experiments to 
demonstrate that the microbiota altered by resveratrol treatment could lead to suppression 
of colitis-associated inflammation.  In the present report, we therefore performed fecal 
transfer experiments, which conclusively demonstrated that resveratrol-mediated 
modulations in the gut microbiota is indeed responsible for attenuating colonic 
inflammation.  It is becoming apparent that the gut microbiome contributes significantly 
to the development and progression of various diseases, particularly in the case of colitis 
(Autenrieth and Baumgart, 2017; Conte et al., 2006; Kanauchi et al., 2003; Nishikawa et 
al., 2009; Rapozo et al., 2017). With the gut microbiome playing such an important role 
in this disease, recent research is even focused on fecal transfer experiments as a 
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therapeutic option (Meighani et al., 2017; Paramsothy et al., 2017). In addition, potential 
treatments against colitis are being examined more thoroughly to determine what, if any, 
effects these possible therapeutics have on the gut microbiome (Jang et al., 2017; Yang et 
al., 2017).  
In the current study, we were able to show that bacteria, such as those belonging 
to the Genus Ruminococcus, are increased during resveratrol treatment, which is 
consistent with animal studies and human fecal transplant experiments in which bacteria 
such as Ruminococcus and others were found to be anti-inflammatory, restoring and 
maintaining normal gastrointestinal tract function and integrity (Satokari et al., 2014). In 
fact, Ruminococcus gnavus and Akkermansia muciniphilia are mucolytic bacteria that are 
found to be reduced in both ulcerative colitis and Crohn’s Disease patients when 
compared to normal patient controls (Png et al., 2010). Therefore, restoration of these 
bacteria, which we noted in our data after naïve mice or TNBS-induced colitis mice were 
treated with resveratrol, could help in restoring or maintaining gut homeostasis, 
particularly after the microbiome is altered during colitis due to microbial dysbiosis. On 
the other hand, the current study shows that resveratrol can effectively reduce 
Bacteroides acidifaciens, which was found to be significantly increased in TNBS-
induced colitis, a finding also seen in a murine DSS model (Kang et al., 2013). B. 
acidifaciens have several features which could lead to the progression and development 
of colitis. This species is known to degrade mucin (Miyamoto and Itoh, 2000), the 
protective layer in the colon producing the host epithelial surface from luminal-bound 
bacteria. B. acidifaciens is also known to increase SCFA production of acetic and 
succinic acids (Miyamoto and Itoh, 2000), both of which can contribute to colitis-
 
26 
associated inflammation. Acetic acid, given in high concentrations, can induce colitis in 
murine models (Karakoyun et al., 2017). Succinic acid, which is produced by members of 
Bacteroidaceae, like B. acidifaciens, was found to be increased in the colons of colitis-
induced mice and when administered by enemas can produce ulcers in the colon (Ariake 
et al., 2000). B. acidifaciens resembles closely another member of the same genus B. 
fragilis, and these bacteria have been shown in the literature to trigger a strong 
inflammatory cascade response, including activation of IL-17-dependent pathways 
(Chung et al., 2018). By decreasing the presence of these bacteria during colitis-
induction, resveratrol might be able to suppress the Th17 response which would normally 
lead to resident tissue destruction and microbial dysbiosis. 
From our present study, we were also able to show that not only does resveratrol 
alter gut microbial composition during colitis disease induction, but these changes in the 
gut microbiome lead to alterations in the production of SCFAs. In particular, we found 
that i-butyric acid was significantly upregulated in resveratrol-treated mice during colitis 
induction and slightly in naïve mice treated with resveratrol compared to those treated 
only with Vehicle. From the literature, we know that butyrate/butyric acid has potent 
anti-inflammatory properties (Dai et al., 2017; van der Beek et al., 2017; Wang et al., 
2017). There are studies that also show that butyrate plays an important role in regulating 
the development of colitis, or acting as an agent to mitigate its deleterious effects (Cobo 
et al., 2017; Zhang et al., 2016c). For example, oral administration of sodium butyrate 
into DSS-induced colitis mice led to reduction of inflammation (Simeoli et al., 2017). 
Butyrate deficiency was shown to increase susceptibility to the development of colitis 
(Meisel et al., 2017). Therefore, the fact that resveratrol was able to increase production 
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of this SCFA, particularly during colitis-induced conditions, provides a better 
understanding of the mechanisms that promote its efficiency against colitis, as well as 
other inflammatory disorders. Interestingly, we saw an increase in acetic acid in 
resveratrol treatment only after colitis induction, and this SCFA is often used to induce 
colitis (Sadraei et al., 2017). It is possible that the increase in butyric acid was able to 
either negate the effects of increased acetic acid in our model. The uniqueness of our 
findings lie in the fact that we were able to show through 16S rRNA gene sequencing and 
fecal transfer experiments that the effectiveness of resveratrol against colitis could be 
explained by the ability of this natural product to alter and reverse microbial dysbiosis 
and SCFA production to promote an anti-inflammatory effect (induction of Treg/IL-10) 
and suppress the inflammatory (Th1/Th17) T cell response, something that has not been 
reported in the literature thus far. It is particularly interesting to note that the poor 
bioavailability of resveratrol during oral consumption, which is attributed to the weak 
aqueous solubility of the compound, has always been an issue in terms to suggesting this 
natural product as a treatment of various disease (Peng et al., 2018). In fact, this 
observation has led to a wealth of research focusing on how to increase the bioavailability 
of this potent anti-inflammatory natural product so that it can be absorbed and circulated 
to various affected organs, such as by way of encapsulation in nanoparticles or some 
other vehicle (Borges et al., 2018; Zu et al., 2018). However, our findings suggest that 
resveratrol alters the microbiome directly and this leads to the anti-inflammatory effects 




 In summary, the current study demonstrates the efficacy of resveratrol to 
attenuate colitis may result from its ability to alter gut microbiota that promotes anti-





Figure 2.1 Gating strategy for flow cytometry.  MLN lymph nodes from control 
(Vehicle) mice were stained and examined by flow cytometry using the following gating 
strategy:  (A) Unstained negative controls were used to eliminate any non-specific false 
positive signal. (B) Single color controls were stained with either CD3 (FITC), CD4 (PE), 
or CD8 (PE-Cy7) to determine appropriate gating for histogram (top) and color dot plots 





Figure 2.2 Treatment with resveratrol reduces clinical symptoms associated with 
TNBS-induced colitis murine model.  Balb/c mice were administered intrarectally with 
1mg of TNBS to induce colitis. Four groups of mice were used:  Vehicle, Resveratrol, 
TNBS+Vehicle and TNBS+Resveratrol. The percent weight loss (A) was determined 
over the course of the study. (B) Survival curve of mice up to day 6 with colitis and those 
treated with RES. Colon lengths (C-D) were measured upon sacrifice (Day 5). Serum 
levels of SAA (E), MPO (F) and Lcn2 (G) were evaluated by ELISA. Endoscopy (H) was 
performed on mice on days 0, 3, and 5. Colonoscopy scores are provided (I). Significance 
(p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way 
ANOVA and post-hoc Tukey’s test. In all data presented in the figure, 5 mice were used 





Figure 2.3 Treatment with resveratrol reduces clinical symptoms associated with 
DSS-induced colitis murine model.  C57BL/6 mice were given 7 days of 3% DSS ad 
libitum followed by regular drinking water for 7 more days. Four groups of mice (n=5 per 
group) were used:  Vehicle, Resveratrol, DSS+Vehicle and DSS+Resveratrol. The 
percent weight loss (A) was determined over the course of the study. Colon lengths (B-C) 
were measured upon sacrifice (Day 10).  Significance of the bar graphs (p-value: *<0.05, 
**<0.01, ***<0.005, ****<0.001) were determined by using one-way ANOVA followed 




Figure 2.4 Treatment with resveratrol prevents cellular infiltration and mucin 
degradation and maintains colon gut structural architecture in TNBS model. The 
study was designed as described in Figure 2.2 legend. Colons (n=5) were excised from 
experimental mice at the endpoint of experiment, fixed in 10% formaldehyde, and 
embedded in paraffin blocks. Cross-section slides containing colons from experimental 
groups were stained using H&E (A) or PAS (B) for histological evaluation. Images of 
stained tissue were taken using both 4x and 20x objectives, and histological scores were 
provided (C). Scale bars (white) depicted are at 100 µM. Data is representative of at least 




Figure 2.5 Resveratrol alters T cell subsets during TNBS colitis. The study was 
designed as described in Figure 2.2 legend.  Flow cytometry histograms/dot plots are 
shown for the following T cell subsets: CD3+ (A), CD4+ or CD8+ cells (B), 
CD4+FOXP3+ (C), CD4+IL10+ (D) and CD4+IFNγ+ (E), and CD4+IL-17+ (F) 
expressing cells. For Figures C-F, cells were gated on the CD4+ population. The gating 
strategy for the CD4+ populations is detailed in Figure 2.1.  Quantitative bar graphs 
depicting absolute cell numbers of the T cell subsets is provided (G) Each experimental 
group had at least 5 mice included, and significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined for absolute cell numbers by using one-way 
ANOVA followed by Tukey’s post-hoc multiple comparisons test. Data is representative 




Figure 2.6 16S rRNA gene sequencing analysis. The study was designed as described 
in Figure 2.2 legend.  Gut microbiome samples were collected from experimental groups 
by performing cecal flushes.  Genomic DNA was isolated and V3-V4 regions of 16S 
rRNA gene subunit were sequenced.  Three randomly selected mice from each group 
(n=3) were used for these experiments.  All sequencing samples were analyzed using 
Nephele software 16S metagenomics provided at Nephele website 
(nephele.niaid.nih.gov). Alpha diversity (A), and Beta diversity (B) are depicted. LeFSe 
analysis of the Nephele OTU output files generated the cladogram (C) and LDA score bar 
graph (D) depicting microbial biomarkers among TNBS+Vehicle vs. TNBS+RES groups. 
OTU percent abundances are shown for the species Bacteroides acidifaciens (E) 
Ruminococcus gnavus (F) and Akkermansia muciphila (G). Validation of these 
significantly-altered bacterial species were performed using PCR and the fold changes 
are calculated using the delta-delta CT method with comparison to Vehicle controls (H-
J). For 16S rRNA gene sequencing, 3 representative cecal flushes from each experimental 
group were processed and sequenced. For PCR validation, 10 mice were used in each 
group and fold changes were calculated using the delta-delta CT method compared to 
Vehicle control. Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was 
determined by using one-way ANOVA followed by Tukey’s post-hoc multiple 




Figure 2.7 16S rRNA sequencing analysis at the phylum to order level.  Gut 
microbiome samples (n=3 per group) were collected from experimental groups (Vehicle, 
Resveratrol, TNBS+Resveratrol, TNBS+Vehicle) by performing cecal flushes.  Genomic 
DNA was isolated and V3-V4 regions of 16S rRNA subunit were sequenced.  Three 
randomly selected mice from each group were used for these experiments.  All 
sequencing samples were analyzed using Nephele software 16S metagenomics provided 
at Nephele website (nephele.niaid.nih.gov). Stacked bar charts depicting OTU relative 
expression with corresponding color-coded legend for the following levels: phylum (A), 




Figure 2.8 16S rRNA sequencing analysis at the family level.  Gut microbiome 
samples were collected from experimental groups (Vehicle, Resveratrol, 
TNBS+Resveratrol, TNBS+Vehicle) by performing cecal flushes.  Genomic DNA was 
isolated and V3-V4 regions of 16S rRNA subunit were sequenced.  Three randomly 
selected mice from each group were used for these experiments.  All sequencing samples 
were analyzed using Nephele software 16S metagenomics provided at Nephele website 
(nephele.niaid.nih.gov). (A) Stacked bar charts depicting OTU relative expression with 
corresponding color-coded legend. (B) Bar graphs representing percent OTU abundance. 
Significance of the bar graphs (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) were 





Figure 2.9 16S rRNA sequencing analysis at the genus level.  Gut microbiome samples 
were collected from experimental groups (Vehicle, Resveratrol, TNBS+Resveratrol, 
TNBS+Vehicle) by performing cecal flushes.  Genomic DNA was isolated and V3-V4 
regions of 16S rRNA subunit were sequenced.  Three randomly selected mice from each 
group were used for these experiments.  All sequencing samples were analyzed using 
Nephele software 16S metagenomics provided at Nephele website 
(nephele.niaid.nih.gov). (A) Stacked bar charts depicting OTU relative expression with 
corresponding color-coded legend. (B) Bar graphs representing percent OTU abundance. 
Significance of the bar graphs (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) were 






Figure 2.10 Resveratrol treatment alters SCFA production in TNBS colitis.  The 
study was designed as described in Figure 2.2 legend.  SCFA were isolated from cecal 
contents of experimental groups through acidification using metaphosphoric acid. GC-
FID analysis was performed to determine the concentrations of acetic (A), propionic (B), 
i-butyric (C), n-buytric (D), i-valeric (E), and n-valeric (F) acids. SCFAs were identified 
using standard compounds purchased from Sigma-Aldrich. Representative data from two 
independent experiments with 5 mice in each group is depicted. Significance (p-value: 
*<0.05, **<0.01, ***<0.005, ****<0.001) was determined using one-way ANOVA 




Figure 2.11 Transfer of resveratrol-treated fecal contents leads to amelioration of 
colitis.  Female Balb/c mice were treated for 4 weeks with streptomycin and ampicillin 
(1g/L) prior to being injected intrarectally with 1mg of TNBS to induce colitis. 
Antibiotic-treated mice were weighed (A) and PCR performed on colonic flush samples 
to determine abundance of bacteria in the gut compared to naïve mice (B-C).  These mice 
received fecal transfer (FT) from either colitis disease groups, (FT) TNBS+Vehicle, or 
from TNBS+Resveratrol-treatment groups, (FT) TNBS+RES.  The percent weight loss 
(D) was determined over the course of the study. Colon lengths were measured upon 
sacrifice (E-F). Serum biomarkers for SAA (G), MPO (H), LCN2 (I) were detected using 
ELISA kits. Endoscopic images (J, top panel) and H&E stains of colons (J, bottom panel) 
are depicted (n=5 per group). Colonoscopy scores (K, top) and histological scores (K, 
bottom) are provided. Cells were isolated from mesenteric lymph nodes of experimental 
groups and absolute cell numbers from fecal transfer experiments were determined for 
CD4+FOXP3+ (L), CD4+IL10+ (M), CD4+IL17+ (N) and CD4+IFNγ+ (O). PCR 
validation from colonic flushes was performed after fecal transfer to confirm alterations 
in Akkermansia muciphila (P) Ruminococcus gnavus (Q) and Bacteroides acidifaciens 
(R), using delta-delta CT method with comparison to Vehicle controls. Each group had 
10 recipient mice in this experiment and significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined using one-way ANOVA followed by Tukey’s 




Figure 2.12 Graphical Abstract. TNBS-induced colitis results in microbial dysbiosis, 
with increased abundance of Bacteroides acidifaciens. However, treatment with 
resveratrol prevents this colitis-associated gut microbial shift, leading to increased 
abundance of bacteria such as Akkermansia muciphila and Ruminococcus gnavus, and 
production of SCFA butyrate. Increased presence of Akkermansia muciphila, 
Ruminococcus gnavus, and butyrate shifts the CD4+ T helper response from Th17 to 
anti-inflammatory Tregs. Fecal transfer of resveratrol-treated mice confirms these 





RESVERATROL ATTENUATES MURINE AOM-DSS INDUCED COLORECTAL 
CANCER BY PROMOTING BUTYRATE PRODUCTION AND INDUCING ANTI-
INFLAMMATORY T CELLS VIA ALTERATIONS IN THE GUT MICROBIOME AND 
SUPPRESSION OF HDACS
3.1 ABSTRACT 
Inflammatory bowel disease (IBD) is known to significantly increase the risk for 
development of colorectal cancer (CRC), thereby suggesting that inflammation and 
cancer development are closely intertwined.  Thus, it is likely that agents that suppress 
inflammation in the colon may prevent the onset of cancer.  In the current study, we 
investigated the effect of resveratrol, a stilbenoid, in inflammation-induced murine model 
of CRC using a combination of azoxymethane (AOM) and dextran sodium sulphate 
(DSS) and tested the role of microbiota in preventing inflammation-driven CRC.  
Resveratrol treatment caused an increase in the levels of anti-inflammatory 
CD4+FOXP3+ and CD4+IL10+ cells while decreasing proinflammatory such as Th1 and 
Th17 cells, as well as attenuated development of CRC in AOM/DSS mice.  Examination 
of colonic contents showed that resveratrol altered the gut microbiome and increased 
levels of the short chain fatty acid (SCFA), butryate.  Fecal transfer from resveratrol-
treated AOM/DSS mice resulted in attenuation of CRC and suppression of inflammation 
as evidenced by alterations in T cell subsets. Moreover, supplementation of butyrate in 
CRC resulted in similar alterations in microbial profile. In vivo and In vitro data also 
revealed both RES and BUT were capable of inhibiting histone deacetylases (HDACs), 
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which correlated with Treg induction.  Interestingly, analysis of TCGA datasets of CRC 
patients, also revealed that increased expression of Treg-specific transcription factor 
FoxP3 or anti-inflammatory IL-10 resulted in an increase in 5-year survival of patients 
with CRC. Together, these data suggest that resveratrol-mediated shift in T cells from 
pro-inflammatory to anti-inflammatory phenotype, in AOM/DSS model, may result from 
alterations in gut microbiome and increased butyrate production leading to attenuation of 
inflammation-driven CRC.  
3.2 INTRODUCTION 
 The current study was undertaken to investigate alterations in the gut microbiome 
by resveratrol during CRC. We show that in the AOM/DSS CRC murine model, 
resveratrol was able to alter the gut microbiome profile and increase microbial-
production of short-chain fatty acid (SCFA), butyrate, to promote an anti-inflammatory T 
cell response (Treg and CD4+IL-10) which decreased disease severity and tumor 
development in the colon. Additionally, fecal transfer of resveratrol-treated fecal material 
and butyrate supplementation experiments showed that modulation of gut microbiota and 
suppression of histone deacetylases (HDACs) were key mechanisms through which 
resveratrol, through butyrate-dependent mechanisms, was able to regulate the immune 
response and prevent CRC development. Lastly, we show that in the human CRC 
population, increased expression of Treg-associated genes (FoxP3 and IL-10) correlates 
with increased survival rates, thereby providing additional proof of the role of anti-
inflammatory environment in CRC suppression. 
 
3.3 MATERIALS AND METHODS 
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Animals. Female C57BL/6 mice (aged 6-8 weeks) were purchased from Jackson 
Laboratories (Bar Harbor, ME) and all mice were housed at the AAALAC-accredited 
animal facility at the University of South Carolina, School of Medicine (Columbia, SC). 
All procedures were performed according to NIH guidelines under protocols approved by 
the Institutional Animal Care and Use Committee (IACUC). 
Induction of AOM/DSS CRC in mice and treatment(s).  To test the efficacy of 
treatment in AOM/DSS-induced CRC model, AOM was purchased from Sigma-Aldrich 
(St. Louis, MO), and administered one time via intraperitoneal (i.p.) injection into 
C57BL/6 mice at a dose of 10 mg/kg at day zero, followed by three cycles of 2% DSS 
(Chem-Impex International, Wood Dale, IL) as previously described (Cui et al., 2010). 
For treatment groups, resveratrol (Sigma-Aldrich) was administered by oral gavage at 
100 mg/kg suspended in 100 µl of water, as previously reported by us (Singh et al., 
2010).  The regimen for resveratrol consisted of administering this compound 24 hours 
prior to the injection of AOM, followed by daily treatment throughout the duration of the 
experiment (10 weeks). Control groups consisted of naïve mice receiving either normal 
water or 100 mg/kg resveratrol. For butyrate supplementation experiments, sodium 
butyrate (BUT) from Sigma-Aldrich was given to mice at 200 mg/kg dissolved in water 
using the same regimen (days and controls) as resveratrol for 10 weeks. 
Procedures for evaluating CRC disease severity. During AOM/DSS induced 
CRC, mice were weighed daily after AOM injection. Animals were euthanized at the 
experimental endpoint (10 weeks after AOM injection) for further evaluation of clinical 
signs to include counting the number and size of tumors in the colon highlighted by 1% 
Alcian blue dye and measured by a ruler or digital caliper. Colonoscopies were 
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performed weekly to experimental groups using a Karl Storz (Tuttlingen, Germany) Tele 
Pack Vet X LED endoscope and scored the following way: 0 = normal colon, 1 = 
presence of blood and tissue sloughing, 2 = presence of 1-2 colonic polyps, 3 = 3-5 
colonic polyps present, 4 = 5-10 colonic polyps present, 5 = <10 polyps present in the 
colon. Colon, mesenteric lymph node (MLN), spleen, and blood were collected from 
euthanized mice for further evaluation. Colons were cleaned by saline wash and 
sectioned for histological analysis. Colon sections (tumor and normal adjacent tissue) 
were fixed with 4% paraformaldehyde and embedded in paraffin, cut into 5µm sections, 
deparaffinized in xylene, serially diluted in decreasing concentrations of ethanol, and 
stained with hematoxylin-eosin (H&E) and Periodic Acid Schiff (PAS) staining kits 
(Sigma-Aldrich). Images of stained sections were taken using a Biotek (Winooski, VT) 
Cytation 5 with digital wide field microscopy capabilities. 
Cellular phenotyping by flow cytometry. Cells from MLN, spleen, and blood 
were isolated from experimental groups and lysed with RBC lysis buffer (Sigma-Aldrich) 
before being filtered and stained with appropriate antibodies for cellular phenotyping 
using flow cytometry. All cells were pre-blocked with Fc receptor, washed with FACS 
staining buffer (PBS with 2% fetal bovine serum), and stained with commercially-
available antibodies (Biolegend, San Diego, CA) as follows: FITC- anti-CD3, PE-anti-
CD8, and PE-CY7-anti-CD4 to identify T cells; FITC-anti-Gr1 and PE-anti-CD11b to 
identify myeloid-derived suppressor cells (MDSCs). For phenotyping of T cell subsets, 
intracellular (Intracellular Staining Permeabilization Wash Buffer) and intranuclear 
(True-Nuclear Transcription Factor Buffer Set) staining kits (Biolegend) were used by 
way of manufactures instructions. Permeabilized cells were stained with PE-Cy7-anti-
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CD4, PE-anti-Foxp3, FITC-anti-IL10, PE-anti-IFNγ, and/or FITC-anti-IL17 (Biolegend). 
Flow cytometry data were analyzed using a CXP FC500 flow cytometry (Beckman 
Coulter, Brea, CA). 
 In vitro treatment of activated splenocytes with resveratrol or BUT. For in 
vitro experiments treated with resveratrol or BUT, whole splenocytes were excised from 
8-10 week old C57BL/6 mice and single cell suspensions were cultured in anti-CD3-
coated (.5µg/ml) 96-well plates at 1 x106 cells/mL density in complete RPMI media for 
24 hours at 37°C, 5% CO2. Cultured cells were then activated with soluble anti-CD28 
(2µg/ml) in the presence or absence of resveratrol (5, 10, or 25 µM) or BUT (1mM, 
5mM, or 10mM) for 24 hours (37°C, 5% CO2). In vitro doses of resveratrol were based 
on previous reports from our lab (Singh et al., 2007). The range of doses for BUT was 
determined using information gathered from other publications (Kespohl et al., 2017; 
Salimi et al., 2017).  
16S rRNA gut microbiota profiling, Phylogenetic Investigation of 
Communities by Reconstruction of Unobserved States (PiCRUSt), and SCFA 
analysis. 16S rRNA gut microbial profiling and SCFA quantification were done as 
previously described in our lab (Chitrala et al., 2017). Briefly, colonic contents were 
collected immediately after euthanasia and gathered in 2 ml eppendorf tubes while under 
anaerobic conditions and stored at −80 °C for downstream analysis purposes. For 16S 
rRNA sequencing, genomic DNA was extracted from 100 mg of colonic flush contents 
by using the QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) according to 
instructions from the manufacturer. DNA libraries were prepped by amplification of the 
16S rRNA V3-V4 hypervariable region with added Illumina adapter overhang nucleotide 
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sequences and sequencing with Illumina (San Diego, CA) MiSeq platform. Sequenced 
reads were than analyzed using Nephele (https://nephele.niaid.nih.gov), an open-source 
analysis tool provided by the National Institute of Allergy and Infectious Diseases 
(NIAID) Office of Cyber Infrastructure and Computational Biology (OCICB) in 
Bethesda, MD (Weber et al., 2018). For microbial profiling, QIIME FASTQ paired end 
with chimera removal, open reference, and SILVA rRNA database project (Silva_99) 
options were used. For PiCRUSt data, a closed reference against the Greengenes database 
(Greengene_99) option was used. Operational taxonomic unit (OTU) tables generated 
from Nephele were further subjected to Linear Discrimination Analysis Effect Size 
(LEfSe) provided by the Huttenhower group 
(https://huttenhower.sph.harvard.edu/galaxy/) (Segata et al., 2011). For quantification of 
SCFAs present in colonic flushes, HP 5890 gas chromatograph configured with flame-
ionization detectors (GC-FID) was performed as previously described (Chitrala et al., 
2017; Zhao et al., 2006). SCFA detection by GC-FID was quantified using Varian MS 
Workstation (version 6.9.2.) software and concentrations were calculated by using 
standards for the detectable SCFAs.   
Fecal transfer (FT) experiments. For FT experiments, colonic contents were 
collected immediately after euthanasia, gathered in 2 ml eppendorf tubes while under 
anaerobic conditions, and placed in 30% glycerol solution prior to inoculation into 
recipient mice. Before FT inoculation, recipient mice were treated with 1g/L of 
streptomycin and penicillin dissolved in water and orally gavaged at 100 µl total volume 
daily for four weeks to deplete endogenous gut microbiota. Depletion of microbiota was 
validated by PCR analysis using the universal 16S rRNA Eubacteria primer. AOM/DSS 
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CRC induction was performed as previously described in recipient mice. 48 hours after 
the last treatment with the antibiotic cocktail, recipient mice were given fecal material 
collected from the following groups: Naïve, Resveratrol-treated only, AOM, and 
AOM+Resveratrol. FT treatments were given via oral gavage every even days for a total 
of 35 days. Body weight and other clinical parameters described previously were also 
performed for the FT experiments to include weekly colonoscopies, 1% Alcian blue 
staining for quantification of colonic tumors, colon histology (H&E and PAS stains), and 
flow cytometry for analysis of T cell subsets.  
Quantitative Real-Time PCR (qRT-PCR) for bacterial species validation and 
HDAC expression. For validation of bacteria identified by 16S rRNA analysis, qRT-
PCR was used with primers designed to identify the 16s rRNA subunit of significantly 
altered bacterial species. DNA was extracted from colonic samples using the QIAamp 
DNA Stool Mini Kit (Qiagen) as previously described. For HDAC expression data, RNA 
was extracted from single cell suspensions of MLN (in vivo) or cultured splenocytes (in 
vitro) using RNeasy Mini kits (Qiagen) followed by conversion to cDNA using iScript 
synthesis kit (Bio-Rad). PCR amplification was performed using QuantiFast (bacteria) or 
QuantiTech (HDAC) SYBR Green PCR kits from Qiagen, and reactions were performed 
on a CFX96 qPCR system from Bio-Rad (Hercules, CA). Primers were designed by 
Intergrated DNA Technologies (Coralville, IA). Sequences for all primers are included in 
Table 3.1.  
Correlation of gene expression with survival in CRC patient data sets. The 
correlation of gene expression pattern with survival of human patients with CRC was 
performed using the TCGA datasets for colorectal cancer from The Cancer genome Atlas 
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maintained at TCGA (https://cancergenome.nih.gov/). TCGA examines the genome-wide 
expression, copy number variations, methylation status and mutations in an immense 
number of samples with a primary advantage such as i) each patient sample is 
accompanied with a comprehensive clinico-pathological data ii) a huge portion of the 
samples with integrated molecular profiles iii) number of matched normals for tumor 
samples iv) generation of data using latest and widely measured standard molecular 
profiling technologies (Bacolod et al., 2015). Survival analysis for the TCGA datasets 
were performed using the Kaplan-Meier survival curves which is defined as the 
probability of survival in a given length of time while considering time in many small 
intervals (Goel et al., 2010). It mainly involves the calculation of the probability of 
occurrence of an event at a certain point of time. 
Statistical analysis and data availability. GraphPad Prism software (San Diego, 
CA) was used for all statistical analysis unless otherwise stated. Experiments were 
repeated at least three times to confirm reproducibility.  For statistical differences, one-
way ANOVA and Tukey’s post-hoc comparison test was used unless otherwise noted in 
the text. Significance was determined to have a p value of ≤ 0.05 (*), 0.01 (**), 0.005 
(***), or 0.001 (****). Raw sequencing data (FASTq files) were uploaded to the NCBI 
Sequence Read Archive (SRA). 
3.4 RESULTS 
Resveratrol attenuates AOM-induced CRC by preventing early onset of 
inflammation and decreasing tumor burden 
To study the effects of resveratrol on CRC in the context of studying host immune 
response and microbiome, we used the well-characterized AOM/DSS CRC murine 
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model. For these studies, experimental groups consisted of naïve mice (Naïve), naïve 
mice treated with only resveratrol (Resveratrol), AOM/DSS disease mice with no 
treatment (AOM), and AOM/DSS disease mice treated with resveratrol 
(AOM+Reservatrol). Inducing CRC by AOM resulted in a significant decrease in body 
weight (~20%) compared to controls (naïve or resveratrol-treated only), but treatment of 
CRC mice with resveratrol reduced this disease-associated weight loss and resulted in 
~8% weight gain by the end of the study (Figure 3.1A). In addition, the administration of 
AOM resulted in decreased survival of mice (~75%) by the end of the study, whereas 
CRC mice treated with resveratrol resulted in 100% survival (Figure 3.1B). Resveratrol 
treatment also was able to reduce tumor burden in AOM-induced CRC mice as assessed 
during the experimental endpoint (10 weeks), as AOM-treated mice developed at least 10 
or more tumor polyps along the colon, whereas AOM+Reservatrol mice had little to no 
tumors polyps present (Figure 3.1C-D). In order to monitor the first signs of 
inflammation and tumor development during disease and treatment, colonoscopies were 
performed weekly among experimental groups. In AOM mice, inflammation 
development, which was characterized by the presence of bloody lesions and tissue 
sloughing along the colon, developed around week 3 of the disease model, but 
AOM+Resveratrol mice maintained more normal appearing colons (Figure 3.2). The 
presence of tumors was seen in AOM mice by week 5 and continued developing to week 
9, but CRC mice treated with resveratrol showed a marked decrease in colonic tumor 
development (Figure 3.1E-F; Figure 3.2).  Colon histology reinforced these observations 
as AOM colons showed loss of normal mucosal architecture and abnormal tissue growth 
with standard H&E staining which was not apparent in AOM+Resveratrol colon sections 
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which more closely resembled controls (Figure 3.1G). PAS staining on fixed colon 
sections was also performed as a way to access mucin production and goblet cell 
formation (Agawa et al., 1988). Mice challenged with AOM showed a high reduction in 
the number of goblet cells and presence of mucus compared to controls, but these 
observations were greatly reversed in colon sections excised from AOM+Resveratrol 
groups (Figure 3.1H). Collectively, these data demonstrated that resveratrol treatment 
attenuated tumor development in the AOM CRC model, perhaps by way of preventing 
early signs of inflammation caused by multiple cycles of DSS, as shown in week 3 of the 
colonoscopy images. 
Resveratrol treatment reduces inflammatory T cell subsets while increasing 
anti-inflammatory T cells in AOM-induced CRC 
In order to examine immune cell alterations during disease and treatment, cells 
were isolated from the MLN, spleen, and blood of all experimental groups and 
phenotyped using flow cytometry (Figures 3.3-3.6). In the MLN, expression of T cell 
marker (CD3+), along with T helper (CD3+CD4+) and cytotoxic T cell (CD3+CD8+), 
were significantly decreased in AOM mice compared to controls, and restoration of these 
T cell phenotypes occurred in the AOM+Resveratrol groups (Figure 3.1I). These data 
suggested that activated T cells in AOM group were leaving MLN and going to the colon 
while resveratrol reversed this.  Similar observations were seen in both the spleen (Figure 
3.4) and the blood (Figure 3.5).  Going further in phenotyping the CD4+ subsets, 
intracellular/intranuclear staining was performed to identify the effect of resveratrol 
inflammatory (IFNγ- and IL17-producing) cells) and to anti-inflammatory (FOXP3+ 
Tregs and IL10-producing) CD4+ T cell populations. The data collected from the MLN 
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showed that there was a significant increase in both anti-inflammatory CD4+FOXP3+ 
(Fig. 1J) and CD4+IL10+ (Figure 3.1K) cells population in AOM mice treated with 
resveratrol when compared with AOM disease mice. However, proinflammatory T cell 
subsets, such as Th17 (Figure 3.1L) and Th1 (CD4+IFNγ+) (Figure 3.1M) were 
significantly higher in AOM mice compared to the controls, but treatment with 
resveratrol was able to effectively reduce these inflammatory T cell phenotypes. This 
shift in the proinflammatory to anti-inflammatory T cell subsets after resveratrol 
treatment was also observed in the spleen (Figure 3.5). Lastly, as MDSCs are known to 
increase in the CRC human population and are thought to be a potential immunotherapy 
target (Sun et al., 2012), data collected from the spleen and blood revealed that MDSCs 
were significantly increased in the AOM disease state, but were effectively reduced by 
treatment with resveratrol (Figure 3.6). Together, these data suggested that resveratrol 
promoted an anti-inflammatory T cell response in the AOM CRC model.   
Alterations in gut microbiota and SCFA composition in AOM-DSS colorectal 
induced mice treated with resveratrol  
In order to determine if resveratrol-mediated alterations in inflammation is 
associated with changes in gut microbiome, we first analyzed the gut microbiota from all 
experimental groups by using 16S rRNA V3-V4 sequencing technique for microbial 
profiling. From colonic fecal matter, we isolated genomic DNA and performed 
pyrosequencing with Illumina MiSeq platform. Nephele analysis output showed that the 
alpha diversity, represented as chao1, was slightly enriched in the AOM and 
AOM+Resveratrol groups compared to controls (Figure 3.7A). In terms of beta diversity, 
depicted as a principle component analysis (PCA) plot, samples clustered within their 
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own respective groups, with resveratrol-treated groups showing more similar diversity 
compared to naïve controls, and the AOM disease group clustering further away from all 
other experimental groups (Figure 3.7B). 16s rRNA sequencing analysis from Nephele 
allowed sample reads to be classified into OTUs from the phylum to the species level 
(Figures. 3.8-3.12), and divergent microbial composition among the experimental groups 
was apparent starting even at the phylum level. At this taxa level, Verrucomicrobia, 
Tenericutes, and TM7 were found to be significantly reduced in abundance within AOM 
groups compared to the controls, whereas levels of these phyla were restored or increased 
in AOM+Resveratrol mice (Figure 3.8). AOM mice also had a slight increase in 
Firmicutes compared to the other groups, and an even more significant increase in 
Proteobacteria, which were reduced to normal levels in the AOM+Resveratrol the 
treatment group (Figure 3.8). At class level, Verrumcomicrobiae, Mollicutes, TM7-3, and 
Alphaproteobacteria were decreased in AOM mice, but found to be restored in most 
cases after treating mice with resveratrol (Figure 3.9). Deltaproteobacteria and Bacilli 
were increased in AOM, and while Deltaproteobacteria levels were reduced to control 
levels the in AOM+Resveratrol groups; in Bacilli, AOM+Resveratrol had the most of this 
class (Figure 3.9). Within the order level, Verrucomicrobiales, Anaeroplasmales, and 
CW040 showed significant reduction in abundance in the disease state when compared to 
the treatment group, while Clostridiales, Turicibacterales, and Desulfovibrionales 
showed significant increases in abundance in AOM mice compared to controls, and in 
AOM+Resveratrol group, these were reduced except for Turicibaterales (Figure 3.10).  
In a continuing trend, some bacteria at the family level, including Verrucomicrobiaceae, 
Dehalobacteriaceae, Anaeroplasmataceae, F16, Lachnospiraceae, Mogibacteriaceae 
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and Closteridiaceae showed a decrease in AOM groups but an increase in the 
AOM+Resveratrol group, whereas Desulfovibrionaceae increased during the untreated 
disease state, but reduced to control levels in AOM+resveratrol group (Figure 3.11). 
Lastly, at genus level Ruminococcus, Akkermansia, Dehalobacterium, Anerostipes, 
Anaeroplasma, Blautia, and Clostridium were reduced in AOM mice compared to 
controls but were restored or increased significantly after treatment with resveratrol 
(Figure 3.12), whereas, Oscillospira and Desulfovibrio increased in AOM, but were 
significantly reduced in AOM+Resveratrol groups (Figure 3.12). As several bacteria were 
altered in the disease and treated states, LEfSe analysis, which is a useful tool to 
determine potential bacterial biomarkers among experimental groups (Segata et al., 
2011), was used to highlight the more relevant significant differences in the microbial 
community. From this analysis, it was found that among the species detected by 16S 
rRNA sequencing, Ruminococcus gnavus, Akkermansia muciniphillia, and Mucispirillum 
schaedleri were among the potential biomarkers in the AOM+Resveratrol treatment 
group (Figure 3.7C-D). As shown in Figure 3.7E, all of these species were significantly 
reduced in AOM mice, but were increased after treatment with resveratrol, and we 
validated these finding using PCR (Figure 3.7F). 
In addition to microbial profiling, we investigated the resulting changes in the 
microbial community altered bacterial-related metabolism, as PiCRUSt allows evaluation 
of bacterial function to be performed with 16S rRNA data (Langille et al., 2013). Using 
combined PiCRUSt (via Nephele) and LEfSe analyses, it was shown that there were 
marked changes in microbial functions amongst the experimental groups particularly 
after treatment with resveratrol, which included those that were connected to CRC (e.g. 
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P53 signaling) (Slattery et al., 2018), and those involved in generation of Tregs (e.g. 
TGF-β signaling) (Becker et al., 2018) (Figure 3.13). Lastly, we determined if changes in 
SCFA production, metabolite produced by gut flora in the host organism (Marchix et al., 
2018), could be seen in response to these changes in the gut microbiome composition 
triggered by treatment of CRC with resveratrol. Examination of colonic contents showed 
that n-buytric and i-butyric acid concentrations were significantly reduced in the AOM 
groups compared to controls. However, AOM group treated with resveratrol restored or 
increased the levels of these SCFAs (Figure 3.7G). Among the other detectable SCFAs, 
propionic acid, i-valeric acid, and n-valeric acid showed no significant changes among 
the experimental groups (Figure 3.7G). Together, these studies demonstrated that 
treatment of CRC-induced mice with resveratrol leads to significant changes in both the 
gut microbial profile and function.  
Fecal transfer from resveratrol-treated groups attenuates AOM/DSS-
induced CRC and alters the T cell-specific immune response: 
In order to determine whether or not resveratrol-induced alterations in the gut 
microbiome were contributing to the altered immune response in CRC, we performed 
fecal transfer (FT) experiments. After receiving antibiotics to deplete the existing gut 
microbiome, AOM-induced CRC recipient mice were inoculated with feces from either 
Naïve, Resveratrol, AOM, or AOM+Resveratrol groups. Mice inoculated with fecal 
material from disease controls, referred to as AOM(FT), showed gradual decrease in 
body weight throughout the study compared to controls, whereas AOM+Resveratrol(FT) 
mice recovered  and gained weight by the end of 10 weeks (Figure 3.14A). 
AOM+Resveratrol(FT) mice also showed increased survival when compared to 
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AOM(FT) mice (Figure 3.14B), along with decreased incidence of tumor development in 
the colon (Figure 3.14C-D). In addition, weekly colonoscopy examination (Figure 3.15) 
showed increased ulceration and sloughing in portions of the colon in mice fed disease-
derived feces, however, mice that were given FT from resveratrol-treated groups showed 
a reduced presence of polyps and abnormal colonic tissue growths at the end of the study 
(Figure 3.14E-F). Histological examination by H&E stains revealed AOM(FT) colon 
tissues had abnormal growth and damage to the mucosal layer, whereas 
AOM+Resveratrol tissues resembled that of control colons (Figure 3.14G). PAS stains 
also showed that AOM(FT) recipients had decreased mucus production and goblet cells, 
and just as with treatment with resveratrol in the AOM disease state, 
AOM+Resveratrol(FT) colon tissues had restored intestinal architecture with normal 
mucus present and distribution of goblet cells (Figure 3.14H).  Together, these FT 
experiments demonstrated that the clinical benefits provided by resveratrol against AOM-
induced CRC can be attributed, at least in part, to changes in gut microbiota. Next, we 
tested if the changes in the gut microbiota induced by resveratrol also resulted in changes 
in inflammation.   
As in the previous experiment, flow cytometry analysis was performed in the FT 
experiments and collected data showed in the MLNs (Figure 3.16) of AOM(FT) mice, a 
marked decrease in both T helper (Figure 3.14I) and cytotoxic T cells (Figure 3.14J), 
whereas AOM+Resveratrol(FT) mice had increased numbers of these cells present in the 
tissue. Going further in phenotyping the CD4+ T helper phenotypes, AOM mice showed 
significant decreases in anti-inflammatory Tregs (Figure 3.14K) and CD4+IL10-
producing cells (Figure 3.14L), which were significantly increased in all resveratrol-
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treated groups. On the other hand, proinflammatory Th17 (Figure 3.14M) and IL17-
producing CD4+ T cells (Figure 3.14N) were found to be significantly higher in 
AOM(FT) recipients compared to the other FT groups, and while AOM+Resveratrol(FT) 
recipients had decreased Th17 phenotype, this group was not able to decrease Th1 
(CD4+IFNγ+) cells. In order to confirm the transfer of feces resembled our previous 
sequencing data, PCR validation was performed showing a similar microbial profile for 
significantly altered species Ruminococcus gnavus and Akkermansia muciniphilia, which 
were decreased in AOM(FT) and increased in the AOM+Resveratrol(FT) group (Figure 
3.14O). Collectively, these data demonstrated that the alterations of microbiome by 
resveratrol were directly modulating the T cell immune response in AOM-induced CRC, 
particularly in increasing anti-inflammatory subsets (Tregs and CD4+IL-10-producers), 
while decreasing proinflammatory types (Th17 and Th1). 
Butyrate supplementation attenuates AOM/DSS-induced CRC and promotes 
an anti-inflammatory T cell response similar to resveratrol: 
In the current study, one of the distinct outcomes gathered regarding resveratrol-
mediated alterations in the gut microbiome was the increase in SCFA butyrate, which is 
known to have anti-inflammatory properties (Sitkin and Pokrotnieks, 2018; van der Beek 
et al., 2017). To test its role further, supplementation with sodium butyrate (BUT) was 
given in lieu of resveratrol to determine the potential effects of increased levels of this 
SCFA produced in the AOM-induced CRC model. To address this, experimental groups 
were designed to mimic the previous experiments with the exception of substituting 
resveratrol with BUT, and these groups included: Naive alone, BUT alone, AOM, and 
AOM+BUT.  As expected, AOM mice had significant decrease in body weight (~20%) 
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compared to controls, but like AOM+Resveratrol groups from the previous experiments, 
AOM+BUT mice had significant reduction in weight loss over time (Figure 3.17A).  
Additionally, while the AOM group had a decrease in overall percent survival, 
AOM+BUT mice showed 100% survival after 10 weeks (Figure 3.17B). Similar to 
AOM+Resveratrol mice, AOM+BUT mice had decreased or nonexistent colonic tumors 
(Figure 3.17C-D). Colonoscopic examination at 5 different time points (weeks 0,3,5,7 
and 9) during the experiment gave a clear picture of the development of CRC-associated 
lesions and tissue sloughing after AOM injection, but AOM+BUT groups showed 
marked decrease in tissue disruption (Figure 3.17E-F, Figure 3.18). Histological 
examination of formalin-fixed colon tissues stained with H&E was also performed on 
experimental groups, which clearly showed in AOM colons there was a loss of mucosal, 
submucosal, and serosa architecture, which was not seen in AOM+BUT (Figure 3.17G). 
PAS staining showed that AOM+BUT colons were also able to maintain significant 
amount of mucus presence and number of goblet cells which were lost in AOM tissue 
sections (Figure 3.17H). Supplementation with butyrate was thus able to attenuate the 
clinical parameters of AOM-induced CRC much like resveratrol, so it was reasonable to 
examine whether or not increased butyrate was able to alter the T cell repertoire. 
Just as with resveratrol treatment, flow cytometric analysis of the MLN (Figure 
3.19) showed expression of T cells in general, CD4+ T helper, and CD8+ cytotoxic T 
cells increased in AOM+BUT groups after being depleted in number in AOM-induced 
CRC (Figure 3.17I). AOM+BUT groups also had increased numbers in anti-
inflammatory Tregs (Fig. 4K) and CD4+IL-10 cells (Figure 3.17L) when compared to 
AOM mice which had much lower number of these cells than the control groups. 
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Alternatively, inflammatory Th17 (Figure 3.17M) and Th1 cells (Figure 3.17N), were 
much lower in AOM+BUT mice when compared to the AOM disease controls, in 
addition to anti-inflammatory CD4+FOXP3+ and CD4+IL10+ populations in both 
mesenteric lymph node and blood. A similar shift from proinflammatory Th17/Th1 to 
anti-inflammatory Tregs/IL-10 was seen after treatment with BUT in the spleen (Figure 
3.20). Collectively, these data showed that butyrate supplementation reduces the 
inflammatory T cell response much in the same manner as resveratrol, suggesting that 
increased production of this SCFA by resveratrol is another mechanism through which 
this natural compound may be effective against AOM-induced CRC. 
Supplementation of butyrate alters the microbial profile in AOM-induced 
CRC with similarities to resveratrol treatment:  
As resveratrol-mediated increases in colonic butyrate could also lead to alterations 
in the microbiome in addition to promoting anti-inflammatory T cell phenotypes, 16S 
rRNA microbial sequencing was performed on experimental groups in the butyrate 
supplementation experiments. Alpha diversity indicated that compared to the naïve 
group, all other experimental groups (BUT, AOM, AOM+BUT) had lower overall 
diversity within the samples (Figure 3.21A). Beta diversity or PCA clustering in the 
butyrate supplementation experiments mimicked closely what was seen in the resveratrol 
treatment experiments, with all experimental samples clustering within their own groups 
tightly, but the AOM group being the most divergent (Figure 3.21B). OTU abundances 
were calculated from the phylum to the genus level (Figure 3.22-3.25) as previously 
done. Several significant differences were seen at taxa levels with butyrate 
supplementation, however, for the current report and in context in explaining resveratrol-
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mediated mechanisms, only those with changes similar to the resveratrol treatment 
experiments are highlighted. For example, BUT-treated groups were able to restore or 
increase bacteria at the phyla Verrucomicrobia and Tenericutes, which were significantly 
reduced in the AOM group, while butyrate supplementation decreased Proteobacteria 
which rose in AOM-induced CRC (Figure 3.22). At the class level, AOM+BUT mice had 
increased Verrucomicrobiae, Mollicutes, and TM7-3 which were significantly reduced in 
AOM disease mice, and the AOM-increased Deltaproteobacteria were reduced after 
butyrate supplementation (Figure 3.23). At the order level, butyrate supplementation 
increased Verrucomicrobiales, Anaeroplasmales, and CW040 much like resveratrol did 
after being decreased in AOM groups, whereas Desulfovibrionales increased during 
AOM disease, but was reduced in the AOM+BUT samples (Figure 3.24). At the family 
level, Verrucomicrobiaceae, Anaeroplasmataceae, Closteridiaceae, Mogibacteriaceae, 
and F16 were all reduced in AOM mice compared to controls as previously shown, 
however, AOM+BUT increased levels of these gut microbials, whereas the increase seen 
in families in AOM samples (Desulfovibrionaceae) were reduced after supplementation 
with butyrate (Figure 3.25). At the genus level and closely mimicking resveratrol 
treatment experiments, Ruminococcus, Akkermansia, Anerostipes, Anaeroplasma, and 
Clostridium were reduced in AOM mice compared to controls but were restored or 
increased significantly after butyrate supplementation, whereas Desulfovibrio increased 
in AOM, but was significantly reduced in AOM+BUT groups (Figure 3.26). LeFSe 
analysis was then performed to determine which bacterial species had the highest LDA 
score among the experimental groups (Figure 3.21C-D), and combined with OTU 
abundance data, Ruminicoccus gnavus and Akkermansia muciniphilia (Fig 3.21E) were 
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found to be restored by butyrate after depletion in AOM-induced CRC, which was 
validated with PCR (Figure 3.21F). Take altogether, these data suggested that resveratrol-
mediated alterations in the gut microbiome and shifting to anti-inflammatory T cell 
phenotype in AOM-induced CRC can be explained, at least in part, by the ability of 
resveratrol to increase levels of butyrate in the gut microenvironment. 
Resveratrol and BUT inhibit HDACs in vivo and in vitro 
The increase in colonic butyrate production in resveratrol-treated CRC mice was 
interesting given the fact that previous reports show butyrate not only increases Treg 
production (Arpaia et al., 2013; Vieira et al., 2019), but the HDAC inhibiting activities of 
this SCFA have been implicated as a key mechanism in which it exerts anti-inflammatory 
and anti-cancer properties (Martin-Gallausiaux et al., 2018; Sethi et al., 2018; Silva et al., 
2018), including in colorectal cancer models (Zhang et al., 2016b). With is in mind, 
studies were performed to examine the ability of resveratrol and BUT to suppress 
HDACs in vitro and in the CRC in vivo model and how this correlated with increased 
Treg production. For in vitro studies, resveratrol increased Tregs in activated splenocytes 
in a dose-dependent manner (Figure 3.27, Figure 3.28A). BUT significantly increased 
Tregs at the higher doses (5 and 10mM) when treating activated cells in the same manner 
(Figure 3.27, Figure 3.28B). Following these observations, the expression of class I 
(HDAC I; HDACs 1, 2, 3, and 8) and class II HDACs (HDAC II; HDACs 4, 5, 6, 7, 9, 
and 10) were examined in cultures with the most significantly increased Treg expression 
(25µM for resveratrol and 5mM for BUT). Resveratrol in the in vitro cultured system was 
able to significantly reduce expression of all HDAC I (Figure 3.28C), but interestingly 
decreased only selective HDAC II, specifically not being able to reduce HDAC 6, 9, and 
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10  (Figure 3.28D). BUT, being a well-known HDAC inhibitor, was able to reduce 
expression of all HDACs, regardless of specific classes (Figure 3.28E-F). Lastly, the 
expression of HDAC I and II was evaluated in in vivo CRC experiments given treatment 
with either resveratrol or BUT. Interestingly, similar results were seen. For HDAC I, 
resveratrol treatment compared to either naïve controls or CRC disease mice resulted in 
decreased expression (Figure 3.28G). While HDAC II were all decreased upon treatment 
with resveratrol compared to naïve controls, once again, select HDACs (HDAC 6, 9, and 
10) were not inhibited by resveratrol compared to AOM disease controls (Figure 3.28H). 
However, supplementation experiments with BUT resulted in overall decreased HDAC 
expression for HDAC I and HDAC II (Figure 3.28I-J). Altogether, this data suggests that 
while increased butyrate can lead to inhibition of HDACs, which correlates to increased 
Treg expansion, resveratrol is able to at least in part reduce select HDAC expression 
itself, independent of butyrate.       
Increased expression of anti-inflammatory T cell markers results in increased 
survival in human CRC patients: 
Lastly, as the current study was able to show that resveratrol modulated the gut 
microbiome to increase anti-inflammatory T cell subsets (Treg and IL-10-producers) 
while decreasing proinflammatory Th17/Th1 types, we examined whether there was any 
correlation between gene expression of T cell-specific makers in CRC patients with 
survival. Looking at the TCGA datasets of CRC patients, it was shown that increased 
expression of Treg-specific transcription factor FoxP3 (Figure 3.29A) or anti-
inflammatory IL-10 (Figure 3.29B) resulted in an increase in CRC 5-year patient 
survival. High expression of TGF-β, known to influence the development of Tregs, also 
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correlated with increased overall survival in the patient population (Figure 3.29C). 
However, high expression of Th-17 associated IL-17 cytokine was just the opposite, as it 
resulted in decreased patient survival, while patients with lower expression of IL-17 had 
increased survival over time (Figure 3.29D). While expression of Th-17 transcription 
factor RORγt was shown to have no difference in CRC patient survival over a 5-year 
period (Figure 3.29E), expansion past 5 years showed that high expression of this 
transcription factor was capable of bringing down overall CRC patient survival (Figure 
3.29F). Just as in the AOM-induced mouse model in the current study, IFNγ expression, 
associated with Th1 cells, didn’t seem to have much effect on CRC patient survival 
(Figure 3.29G), but in the context of Th1-specific transcription factor (Tbx21), high 
expression of this gene did appear to decrease the expected overall CRC patient survival. 
The results in the current study are promising given that T cell differentiation altered by 
resveratrol towards anti-inflammatory phenotype, via modulation of the gut microbiome, 
appears to have significant impact in overall human CRC patient survival. 
3.5 DISCUSSION 
Published reports with resveratrol date back to the late 1970s, and since then 
research has shown that this natural plant polyphenol has therapeutic properties ranging 
from anti-inflammatory (Koushki et al., 2018), anti-oxidant (Samsamikor et al., 2016; 
Singh et al., 2011a), anti-depressant (de Oliveira et al., 2018; Finnell et al., 2017), anti-
atherogenic (Riccioni et al., 2015), anti-aging (Li et al., 2017), as well as anti-cancer 
(Guan et al., 2012; Ko et al., 2017; Singh et al., 2011b). Our lab has published 
extensively on the anti-inflammatory properties of resveratrol in various disease models, 
showing often how the effects of this compound are AhR-dependent (Alghetaa et al., 
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2018; Chen et al., 2015b; Rieder et al., 2012; Singh et al., 2007; Singh et al., 2010). 
Activation of AhR by known ligands, such as resveratrol, has been shown by us as well 
as others to have significant impact on T cell development and phenotype (Busbee et al., 
2013; Ehrlich et al., 2018). For example, we have shown that activation of AhR by 
dietary indoles in a delayed-type hypersensitivity (DTH) model is essential for shifting 
the T cell response from a proinflammatory Th17 to an anti-inflammatory Treg 
phenotype (Singh et al., 2016). This is important in regards to CRC as studies have 
shown that high expression of Tregs in CRC patients indicate a more favorable prognosis 
(Hu et al., 2017; Xu et al., 2017), whereas increased Th17 has been linked to CRC 
pathogenicity and tumor development (Bedoui et al., 2018; Lee et al., 2017; Yan et al., 
2018). The current report reinforces this notion, as gene expression data of CRC patients 
seemed to indicate that high expression of anti-inflammatory T cell factors (FoxP3, IL-
10) improved patient survival, whereas proinflammatory makers linked to Th17 and Th1 
phenotypes decreased overall survival in the patient population. It is important to note 
that in the context of cancer, the exact role of Tregs/Th17 is not so clear, as other reports 
indicate that Tregs promote cancer development, whereas inflammatory Th17 cells 
prevent tumor invasion and metastasis (Amicarella et al., 2017; Timperi et al., 2016; 
Zhuo et al., 2015). Reports seem to indicate that the role these T cell phenotypes in 
cancer largely depends on the type of cancer along with the stage of disease severity, as 
well as whether the cancer is driven by chronic inflammation, which could explain the 
conflicted reports. For CRC, which is linked to chronic inflammation in the colon, an 
anti-inflammatory response may be more favorable, at least in terms of the early stages of 
the disease. This could explain why our lab as well as others have shown resveratrol as an 
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effective preventative treatment in CRC animal models (Altamemi et al., 2014; Cui et al., 
2010; Huderson et al., 2018; Lee et al., 2018), which is in part due to the ability of this 
compound to shift from a proinflammatory T cell response to anti-inflammatory one. 
While the ability of resveratrol to illicit this type of immune response has been well-
characterized, the significance of this report is in the fact that resveratrol-mediated 
modulation of the gut microbiome seems to be an important mechanism in promoting this 
T cell shift. 
A recent report by Wong et al. showed that inoculation with feces from CRC 
patients in germ-free or conventional mice resulted in an increase in colonic tumor 
development, proinflammatory markers, and Th17 phenotype (Wong et al., 2017). These 
findings are interesting because in addition to promoting the idea of Th17 as CRC-
inducing in nature as discussed already, this report showed that microbiota plays an 
important role in CRC development and progression. Prior to and since this report, it has 
been well-established that the complex interaction between microbiota and the host 
immunity play major roles in CRC pathogenicity (Chen, 2018; Yang et al., 2018b). For 
example, several bacteria, such as Helicobacter pylori, Streptococcus bovis, Bacteroides 
fragilis, and Clostridium septicum have been known to be major contributors to CRC 
development (de Almeida et al., 2018). Even shifts in certain phylum, such as increases 
in Proteobacteria, have been associated with CRC malignancy (Mori et al., 2018). Thus, 
it would stand to reason that therapeutics directed at combating CRC disease would also 
be able to modulate the gut microbiome to promote more beneficial effects.  
Previous reports have shown that resveratrol was capable of altering the gut 
microbiome in other disease models (Etxeberria et al., 2015; Qiao et al., 2014). In line 
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with the current study, researchers found that resveratrol was able to increase bacteria 
such as Verrucomicrobia and Akkermansia muciniphila, while decreasing Bacteroides, 
Dysgonomonas, and Turicibacter in a hypertension model with high-fructose diet (Tain et 
al., 2018). Additionally, in an obesity model it was found that resveratrol treatment 
increased Akkermansia and Ruminococcaceae, which were shown to alleviate the clinical 
effects associated with a high-fat diet (Zhao et al., 2017). Interestingly enough, studies 
found that Ruminococcus gnavus was in fact reduced in CRC patients when compared to 
controls (Chen et al., 2012), and that Akkermansia muciniphilia was associated with 
increased response to chemotherapy in CRC patients (Cani, 2018). The current study 
showed that these species were decreased in AOM-induced CRC, which correlates well 
with human CRC patients, but more importantly, resveratrol was able to restore or 
increase these bacteria. This could further explain why resveratrol is such an effective 
therapeutic in CRC models, as it seems to increase the presence of bacteria lost or 
decreased during CRC development and progression. These particular bacteria appear to 
possess properties essential for controlling and preventing tumor development in the 
gastrointestinal system. 
Alterations in the microbial profile were not the only interesting aspect obtained 
from the current studies, but rather it was significant to find that resveratrol-mediated 
alterations in the gut microbiome promoted SCFA, butyrate, production as well. Butyrate 
has been shown to act in an anti-inflammatory manner in various disease models. For 
example, supplementation with sodium butyrate was capable of attenuating diabetes-
associated inflammation (Xu et al., 2018), as well as inflammation linked to high-fat-diet-
induced non-alcoholic fatty liver disease (Sun et al., 2018). Oral administration of 
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butyrate was also shown to reduce microbial-associated gastrointestinal inflammation and 
liver disease in Gulf War illness by mechanisms such as decreasing inflammatory-
mediated toll-like receptor (TLR) activation (Seth et al., 2018). In the context of CRC 
specifically, decreases in butyrate production are linked to CRC development (Chen and 
Vitetta, 2018), and it was shown that butyrate inhibited aberrant epigenetic modifications 
in CRC cells by upregulating α-ketoglutarate, which is important in mediating DNA 
methylation (Sun and Zhu, 2018). A more recent report closely linked to the current one 
showed that a mix of SCFA (butyrate, acetate, and propionate) was protective against 
AOM-induced CRC and was able to suppress key inflammatory cytokines such as IL-6 
and inducing apoptosis in tumor-associated epithelial cells (Tian et al., 2018). However, 
in our studies, we focused solely on butyrate supplementation and showed that this SCFA 
could alter T cells in CRC specifically by shifting from inflammatory Th1/Th2 to anti-
inflammatory Treg/IL-10-producers. One of the key mechanisms butyrate has been 
shown to promote an anti-inflammatory response is through inhibition of HDACs(Patnala 
et al., 2017; Zhang et al., 2016a), even in the case of promoting Treg production 
specifically in CRC (Zhang et al., 2016b). Interestingly though, the results in the current 
report seemed to suggest that resveratrol alone was promoting HDAC inhibition, 
independent of butyrate, and this correlated with induction of Tregs. However, it is 
important to note that resveratrol treatment in CRC resulted in increased colonic butyrate 
levels, and the T cell subsets were examined in the gut-specific draining lymph node 
(MLN). Therefore, the relationship between resveratrol modulation of the gut 
microbiome, increased butyrate, HDAC expression, and Treg expansion needs to be 
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further analyzed at the local site, in this case the colon, to further understand the interplay 
related to these mechanisms.  
Combined with the findings discussed above, the current study is able to provide 
new and exciting insights into how resveratrol has the potential to be a strong preventive 
agent against CRC. As the gut microbiota is now known to be important in disease 
progression and development, the fact that resveratrol can modulate this 
microenvironment in such a way as to induce a beneficial T cell immune response proven 
to help CRC patients is important, and through FT experiments, this resveratrol-mediated 
mechanism linked to microbiome-modulation appears more conclusive now. In addition, 
to our knowledge, this is the first report to confirm this and also provide evidence that 
resveratrol modulates the microbiome to increase butyrate production.  Our studies also 
suggest that resveratrol and other dietary AhR ligands may constitute preventive 
modalities in the fight against CRC and potentially other types of inflammatory diseases 
linked to microbial dysbiosis.
 
68 
Table 3.1. Primer Sequences 













HDAC 1 CCGCATGACTCACAATTTGCT TCTGGGCGAATAGAACGCAGG 
HDAC 2 TACAACAGATCGCGTGATGAC TCCCTTTCCAGCACCAATATC 
HDAC 3 GAAATGTTGCCCGGTGTTGGA TGAGTTCTGATTCTCGATGCG 
HDAC 4 AACTTCTTCCCAGGAAGTGGA TGCGATAGGCATAACCACCGT 
HDAC 5 TGGACTGGGATATTCACCATG AGAGCCTGGAAAGAAGTTCCC 
HDAC 6 ATTGCTGCTTTCCTGCACATC AATCAACTTGCCTCCTGCCAA 
HDAC 7 GCTGAAGAATGGCTTTGCTGT AATGAGGATCTTGCTGGCTTT 
HDAC 8 AGTGCCTGATTGACGGGAAGT CGGTCAAATTTCCGTCGCAAT 
HDAC 9 AGGATGATGATGCCTGTGGTG GCCTGGTCAAATTCTGGTGCT 




Figure 3.1 Treatment with resveratrol reduces clinical symptoms and alters T cell 
phenotype in AOM-induced CRC model.  C57BL/6 mice were injected intraperitoneal 
with 10 mg of AOM followed by 3 cycles of 2% DSS, to induce CRC. Experimental 
groups consisted of: Naïve (n=6), Resveratrol (n=6), AOM (n=6), and AOM+Resveratrol 
(n=6). Clinical parameters consisted of percent weight loss (A) and survival (B), (C) 
Representative colons stained with 1% Alcian blue, (D) Bar graph depicting number of 
tumors counted in each experimental group, (E) Representative colonoscopic images 
from experimental groups, (F) Bar graph depicting scores after examination of tumor 
polyps detected during colonoscopies, (G) Representative colon sections stained with 
H&E; scale bar = 100 µM at 40x objective, (H) Representative colon sections with PAS 
staining; scale bar = 100 µM at 40x objective, (I) Bar graphs depicting absolute cell 
numbers in MLN for all T cells (CD3+), T helper (CD3+CD4+), and cytotoxic 
(CD3+CD8+) T cells. (J-M) Bar graphs depicting absolute cell numbers in MLN for 
Tregs (J), Th cells producing IL-10 (K), Th17 (L), and Th1 (M) cells. Significance (p-
value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way 
ANOVA and post-hoc Tukey’s test for bar/dot graphs, Mann-Whitney test for weight 





Figure 3.2 Weekly colonoscopy images in AOM-induced CRC treated with 
resveratrol. Induction of AOM CRC and treatment with resveratrol were performed as 
described in Figure 3.1 legend.  (A) Representative colonoscopies are shown from 
experimental groups which included Naïve (n=6), Resveratrol (n=6), AOM (n=6), 
AOM+Resveratrol (n=6) at weeks 1, 3, 5, and 7. Bar graphs depict colonoscopy scores 
(described in Materials and Methods) for experimental groups at week 1(B), week 3 (C), 
week 5 (D), and week 7 (E). Significance (p-value: *<0.05, **<0.01, ***<0.005, 
****<0.001) was determined by using one-way ANOVA followed by Tukey’s post-hoc 










Figure 3.3 T cell phenotyping in MLN of AOM-induced CRC mice treated with 
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as 
described in Figure 3.1 legend.  Representative flow cytometry histograms and dot plots 
are depicted for the following T cell subsets: CD3+ (A), CD3+CD4+CD8+ (B), 
CD4+FOXP3+ (C), CD4+IL10+ (D) and CD4+IFNγ+ (E), and CD4+IL-17+ (F). For 





Figure 3.4 T cell phenotyping in spleen of AOM-induced CRC mice treated with 
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as 
described in Figure 3.1 legend.  Flow cytometry dot plots and quantitative bar graphs 
depicting absolute cell numbers are shown respectively for the following T cell subsets: 
CD3+ (A-B), CD4+ or CD8+ cells (C-E), CD4+FOXP3+ (F-G), CD4+IL10+ (H-I) and 
CD4+IFNγ+ (J-K), and CD4+IL-17+ (L-M) expressing cells. For Figures F-M, cells were 
gated on CD4+ population. Each experimental group had at least 5 mice included, and 
significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined for 
absolute cell numbers by using one-way ANOVA followed by Tukey’s post-hoc multiple 




Figure 3.5 T cell phenotyping in blood of AOM-induced CRC mice treated with 
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as 
described in Figure 3.1 legend.  (A) Representative flow cytometry plots are depicted 
showing CD3+ histogram (top) and CD4+/CD8+ dot plots (bottom) from experimental 
groups. (B) Bar graphs showing absolute cell numbers for the following T cell subsets 
respectively: CD3+, CD3+CD4+ (T helper), and CD3+CD8+ (cytotoxic T cells). 
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by 
using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test in bar 












Figure 3.6 MDSCs in the spleen and blood of AOM-induced CRC mice treated with 
resveratrol. Induction of AOM CRC and treatment with resveratrol was performed as 
described in Figure 3.1 legend.  (A) Representative flow cytometry dot plots are depicted 
showing MDSCs (CD11b+GR1+) in the spleen (top) and blood (bottom) from 
experimental groups. (B) Bar graphs showing absolute cell numbers for MDSCs in the 
spleen. (C) Bar graphs showing absolute cell numbers for MDSCs in the blood. 
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by 
using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test in bar 


















Figure 3.7 16S rRNA sequencing analysis during AOM-induced CRC treated with 
resveratrol. The study was designed as described in Figure 3.1 legend.  Gut microbiome 
samples were collected from experimental groups by performing colonic flushes in 
experimental groups, which were: Naïve (n=7), Resveratrol (n=9), AOM (n=10), and 
AOM+Resveratrol (n=9).  Nephele analysis (nephele.niaid.nih.gov) was used to generate 
charts for chao1 alpha diversity (A) and PCA beta diversity (B). LeFSe analysis of the 
Nephele OTU output files generated the cladogram (C) and LDA score bar graph (D). (E) 
OTU percent abundances are shown in bar graphs for the species Ruminococcus gnavus, 
Akkermansia muciniphila, and Mucispirillums schaedleri.  (F) PCR validation of 
Ruminococcus gnavus, Akkermansia muciniphila, and Mucispirillums schaedleri. (G) Bar 
graphs representing concentration of SCFAs acetic acid, propionic acid, i-butyric acid, n-
butyric acid, i-valeric acid, and n-valeric acid. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test for depicted bar graphs. Experiments are 




Figure 3.8 Significantly altered bacteria in AOM-induced CRC sample treated with 
resveratrol at the phylum level. Induction of AOM CRC and treatment with resveratrol 
was performed as described in Figure 3.1 legend, and 16S rRNA sequencing was 
performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 
















Figure 3.9 Significantly altered bacteria in AOM-induced CRC sample treated with 
resveratrol at the class level. Induction of AOM CRC and treatment with resveratrol 
was performed as described in Figure 3.1 legend, and 16S rRNA sequencing was 
performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 
















Figure 3.10 Significantly altered bacteria in AOM-induced CRC sample treated 
with resveratrol at the order level. Induction of AOM CRC and treatment with 
resveratrol was performed as described in Figure 3.1 legend, and 16S rRNA sequencing 
was performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 














Figure 3.11 Significantly altered bacteria in AOM-induced CRC sample treated 
with resveratrol at the family level. Induction of AOM CRC and treatment with 
resveratrol was performed as described in Figure 3.1 legend, and 16S rRNA sequencing 
was performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 












Figure 3.12 Significantly altered bacteria in AOM-induced CRC sample treated 
with resveratrol at the genus level. Induction of AOM CRC and treatment with 
resveratrol was performed as described in Figure 3.1 legend, and 16S rRNA sequencing 
was performed as described in Figure 3.7 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 











Figure 3.13 LefSe analysis of Nephele-generated PiCRUSt data investigating 
bacterial function based on 16S rRNA sequencing. To study functional changes within 
the microbial samples collected, Nephele-based was performed using the PiCRUSt 
option, which requires a closed reference against the Greengenes database 
(Greengene_99) at taxa levels 2 and 3 for KEGG annotations of the uploaded dataset. 
LefSe was performed using the OTU table generated from the Nephele output analysis 















Figure 3.14 Results from FT experiments in AOM-induced CRC model.  Antibiotic-
treated C57BL/6 mice were injected i.p. with 10 mg of AOM to induce colorectal cancer 
followed by 3 cycles of 2% DSS. Fecal material was inoculated into recipient mice from 
the following donors: Naïve (n=4), Resveratrol (n=4), AOM (n=4), and 
AOM+Resveratrol (n=4). Clinical parameters consisted of percent weight loss (A) and 
survival (B), both which were found to have significant differences in AOM(FT) vs. 
AOM+Resveratrol(FT) groups. (C) Representative colons stained with 1% Alcian blue. 
(D) Bar graph depicting number of tumors counted in each experimental group. (E) 
Representative colonoscope images from experimental groups. (F) Bar graph depicting 
scores after examination of tumor polyps detected during colonoscopies. (G) 
Representative colon sections stained with H&E; scale bar = 100 µM at 40x objective. 
(H) Representative colon sections which underwent PAS staining; scale bar = 100 µM at 
40x objective. (I-J) Bar graphs depicting absolute cell numbers in MLN for general T 
cells T helper (I), and cytotoxic (J) T cells. (K-N) Bar graphs depicting absolute cell 
numbers in MLN for Tregs (K), Th cells producing IL-10 (L), Th17 (M), and Th1 (N) 
cells. (O) PCR validation for the bacterial species Ruminococcus gnavus and 
Akkermansia muciniphila. Significance (p-value: *<0.05, **<0.01, ***<0.005, 
****<0.001) was determined by using one-way ANOVA and post-hoc Tukey’s test for 
bar/dot graphs, Mann-Whitney test for weight data, and log rank test for survival curve. 




Figure 3.15 Weekly colonoscopy images in FT experiments. Induction of AOM CRC 
and FT were performed as described in Figure 3.14 legend.  (A) Representative 
colonoscopies  are shown from experimental groups which included Naïve(FT) (n=4), 
Resveratrol(FT) (n=4), AOM(FT) (n=4), AOM+Resveratrol(FT) (n=4) at weeks 1, 3, 5, 
and 7. Bar graphs depict colonoscopy scores (described in Materials and Methods) for 
experimental groups at week 1(B), week 3 (C), week 5 (D), and week 7 (E). Significance 
(p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by using one-way 











Figure 3.16 T cell phenotyping in MLN of FT experiments. Induction of AOM CRC 
and FT were performed as described in Figure 3.14 legend.  Representative flow 
cytometry dot plots are depicted for the following T cell subsets: CD3+CD4+CD8+ (A), 
CD4+FOXP3+ (B), CD4+IL10+ (C) and CD4+IFNγ+ (D), and CD4+IL-17+ (E). For 





Figure 3.17 Treatment with sodium butyrate (BUT) reduces clinical symptoms and 
alters T cell phenotype in AOM-induced CRC model.  Female C57BL/6 mice were 
injected intraperitoneal with 10 mg of AOM to induce colorectal cancer followed by 3 
cycles of 2% DSS. Experimental groups consisted of: Naïve (n=4), BUT (n=4), AOM 
(n=4), and AOM+BUT (n=4). Clinical parameters consisted of percent weight loss (A) 
and survival (B), both of which were found to have significant differences in AOM vs. 
AOM+Resveratrol groups. (C) Representative colons stained with 1% Alcian blue. (D) 
Bar graph depicting number of tumors counted in each experimental group. (E) 
Representative colonoscopic images from experimental groups. (F) Bar graph depicting 
scores after examination of tumor polyps detected during colonoscopies. (G) 
Representative colon sections stained with H&E; scale bar = 100 µM at 40x objective. 
(H) Representative colon sections which underwent PAS staining; scale bar = 100 µM at 
40x objective. (I) Bar graphs depicting absolute cell numbers in MLN for general T cells 
(CD3+), T helper (CD3+CD4+), and cytotoxic (CD3+CD8+) T cells. (J-M) Bar graphs 
depicting absolute cell numbers in MLN for Tregs (J), Th cells producing IL-10 (K), 
Th17 (L), and Th1 (M) cells. Significance (p-value: *<0.05, **<0.01, ***<0.005, 
****<0.001) was determined by using one-way ANOVA and post-hoc Tukey’s test for 
bar/dot graphs, Mann-Whitney test for weight data, and log rank test for survival curve. 




Figure 3.18 Weekly colonoscopy images in AOM-induced CRC treated with BUT. 
Induction of AOM CRC and treatment with resveratrol was performed as described in 
Figure 3.17 legend.  (A) Representative colonoscopies are shown from experimental 
groups which included Naïve (n=4), BUT (n=4), AOM (n=4), AOM+BUT (n=4) at 
weeks 1, 3, 5, and 7. Bar graphs depict colonoscopy scores (described in Materials and 
Methods) for experimental groups at week 1(B), week 3 (C), week 5 (D), and week 7 (E). 
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by 
using one-way ANOVA followed by Tukey’s post-hoc multiple comparisons test for 








Figure 3.19 T cell phenotyping in MLN of AOM-induced CRC mice treated with 
BUT. Induction of AOM CRC and treatment with resveratrol was performed as described 
in Figure 3.17legend.  Representative flow cytometry histograms and dot plots are 
depicted for the following T cell subsets: CD3+ (A), CD3+CD4+CD8+ (B), 
CD4+FOXP3+ (C), CD4+IL10+ (D) and CD4+IFNγ+ (E), and CD4+IL-17+ (F). For 





Figure 3.20 T cell phenotyping in spleen of AOM-induced CRC mice treated with 
BUT. Induction of AOM CRC and treatment with resveratrol was performed as described 
in Figure 3.17 legend.  Flow cytometry dot plots and quantitative bar graphs depicting 
absolute cell numbers are shown respectively for the following T cell subsets: CD3+ (A-
B), CD4+ or CD8+ cells (C-E), CD4+FOXP3+ (F-G), CD4+IL10+ (H-I) and 
CD4+IFNγ+ (J-K), and CD4+IL-17+ (L-M) expressing cells. For Figures F-M, cells were 
gated on CD4+ population. Each experimental group had at least 5 mice included, and 
significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined for 
absolute cell numbers by using one-way ANOVA followed by Tukey’s post-hoc multiple 




Figure 3.21 16S rRNA sequencing analysis during AOM-induced CRC treated with 
BUT. AOM induction and treatment with BUT were performed as described in Figure 
3.17 legend.  Gut microbiota samples were collected from experimental groups by 
performing colonic flushes in experimental groups, which were: Naïve (n=5), BUT 
(n=5), AOM (n=5), and AOM+BUT (n=5).  Nephele analysis (nephele.niaid.nih.gov) 
was used to generate charts for chao1 alpha diversity (A) and PCA beta diversity (B). 
LeFSe analysis of the Nephele OTU output files generated the cladogram (C) and LDA 
score bar graph (D). (E) OTU percent abundances are shown in bar graphs for the species 
Ruminococcus gnavus and Akkermansia muciniphila.  (F) PCR validation of 
Ruminococcus gnavus and Akkermansia muciniphila. Significance (p-value: *<0.05, 
**<0.01, ***<0.005, ****<0.001) was determined by using one-way ANOVA followed 
by Tukey’s post-hoc multiple comparisons test for depicted bar graphs. Experiments are 





Figure 3.22 Significantly altered bacteria in AOM-induced CRC sample treated 
with BUT at the phylum level. Induction of AOM CRC and treatment with resveratrol 
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was 
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 











Figure 3.23 Significantly altered bacteria in AOM-induced CRC sample treated 
with BUT at the class level. Induction of AOM CRC and treatment with resveratrol was 
performed as described in Figure 3.17legend, and 16S rRNA sequencing was performed 
as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01, ***<0.005, 
****<0.001) was determined by using one-way ANOVA followed by Tukey’s post-hoc 









Figure 3.24 Significantly altered bacteria in AOM-induced CRC sample treated 
with BUT at the order level. Induction of AOM CRC and treatment with resveratrol 
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was 
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 










Figure 3.25 Significantly altered bacteria in AOM-induced CRC sample treated 
with BUT at the family level. Induction of AOM CRC and treatment with resveratrol 
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was 
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 













Figure 3.26 Significantly altered bacteria in AOM-induced CRC sample treated 
with BUT at the genus level. Induction of AOM CRC and treatment with resveratrol 
was performed as described in Figure 3.17 legend, and 16S rRNA sequencing was 
performed as described in Figure 3.21 legend. Significance (p-value: *<0.05, **<0.01, 
***<0.005, ****<0.001) was determined by using one-way ANOVA followed by 
Tukey’s post-hoc multiple comparisons test in bar graphs. Experiments are representative 








Figure 3.27 Resveratrol and BUT dose-dependently increase Tregs in vitro. Whole 
splenocytes (seeded at 1 x 106 cells/ml) from 8-10 week old C57BL/6 mice were 
activated using CD3 (.5µg/ml) and CD28 (2µg/ml) in the absence or presence of 
appropriate vehicle control, resveratrol (5, 10, or 25µM), or BUT (1, 5, or 10mM). After 
24 hours, cells were fixed and stained with antibodies to identify percentages of Tregs 
(CD4+FoxP3+). Plots are representative flow dot plots for vehicle control and the various 
doses of RES and BUT gated on the CD4 population. A total of 3 independent wells 















Figure 3.28 Treatment with Resveratrol and BUT leads to HDAC suppression. 
Whole splenocytes (seeded at 1 x 106 cells/ml) from 8-10 week old C57BL/6 mice were 
activated using CD3 (.5µg/ml) and CD28 (2µg/ml) in the absence or presence of 
appropriate vehicle control, resveratrol (5, 10, or 25µM), or BUT (1, 5, or 10mM). Tregs 
were identified by flow cytometry as represented in Figure 3.27. (A) Treg percentages 
after treatment with various doses of resveratrol. (B) Treg percentages after treatment 
with varying doses of BUT. Fold change expression as assessed by PCR for HDAC I (C) 
and HDAC II (D) after treatment with resveratrol (25µM). Fold change expression as 
assessed by PCR for HDAC I (E) and HDAC II (F) after treatment with BUT (5mM). 
Expression of HDAC I (G) and HDAC II (H) was evaluated from MLNs isolated from 
experimental groups (Naive, Resveratrol, AOM, and AOM+Resveratrol). Expression of 
HDAC I (I) and HDAC II (J) was evaluated from MLNs isolated from experimental 
groups (Naive, BUT, AOM, and AOM+BUT). For in vitro experiments, each group 
consisted of 3 wells (n=3), and the data are representative of 2 independent experiments. 
For in vivo experiments, each group consisted of 5 mice (n=5), and the data is 
representative of at least 3 independent experiments.Significance (p-value: *<0.05, 
**<0.01, ***<0.005, ****<0.001) was determined by using one-way ANOVA followed 




Figure 3.29 Human CRC patient survival correlated with gene expression. TCGA 
datasets for colorectal cancer from The Cancer genome Atlas maintained at (TCGA, 
https://cancergenome.nih.gov/) were used to correlate gene expression with patient 
survival over a 5-year period or more. Correlations to patient survival were performed 
based on the following gene expressions: (A) FoxP3, (B) IL-10, (C) TGF-β, (D) IL-17A, 
(E) ROR-γt, (F) ROR-γt (past five year interval), (G) IFN-γ, and (H) Tbx21.  Kaplan-
Meier survival curves, defined as the probability of survival in a given length of time 





RESVERATROL DOWNREGULATES MIR-31 TO PROMOTE CD4+FOXP3+ T 
REGULATORY CELLS DURING PREVENTION OF TNBS-INDUCED COLITIS
4.1 ABSTRACT 
Colitis, an inflammatory bowel disease, is associated with aberrant regulation of 
the colonic mucosal immune system. Resveratrol, a natural plant product, has been found 
to exert anti-inflammatory properties and attenuate the development of murine colitis. In 
the current study, we examined the role of microRNA (miR) in the ability of resveratrol 
to suppress colonic inflammation. Resveratrol treatment of mice bearing TNBS-induced 
colitis improved the overall clinical scores by reversing weight loss and colitis-associated 
pathogenesis. Flow cytometric analysis of the mesenteric lymph nodes (MLNs) 
demonstrated that resveratrol reduced colitis-associated induction of inflammatory T cells 
(Th17 and Th1) while increasing CD4+Foxp3+ regulatory T cells (Tregs) and IL-10-
producing CD4+ T cells.  miR microarray analysis and PCR validation from CD4+ cells 
isolated from MLN showed that treatment with resveratrol decreased the expression of 
several miRs (miR-31, Let7a, miR-132) that targeted cytokines and transcription factors 
involved in anti-inflammatory T cell responses (Foxp3 and TGF-β). Transfection studies 
with FoxP3-targeting miR-31 mimic or inhibitors confirmed that this miR directly 
regulated the expression of Foxp3.  Analysis of data from human patients with ulcerative 
colitis (UC) revealed that miR-31 expression was significantly increased when compared 
to controls and additionally, this miR was highly induced in UC colon biopsies that 
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exhibited colon cancer-associated neoplastic lesions. Together, the current study 
demonstrates resveratrol-mediated attenuation of colitis may be regulated by miR-31 
through induction of Foxp3+ Tregs and that miR-31 may serve as a therapeutic target for 
human colitis. 
4.2 INTRODUCTION 
 Previously, we have shown that treatment with resveratrol, a natural product 
found in a variety of plant products (Busbee et al., 2013), is able to lessen disease burden 
in chemical (dextran sodium sulfate, DSS) and genetic (IL-10 knockout) models of colitis 
(Singh et al., 2010; Singh et al., 2012), as well as colitis-associated colon cancers 
(Altamemi et al., 2014; Cui et al., 2010). A current review by Nunes et al. highlights 
findings from our lab as well as others showing the effectiveness of resveratrol in 
ameliorating or preventing animal models of colitis (Nunes et al., 2018). One of the key 
findings from our previous report in the colitis-associated tumorigenesis model was that 
resveratrol was able to regulate several microRNAs (miRs) that modulated inflammatory 
genes and factors (Altamemi et al., 2014). This was a significant finding because miRs, 
small non-coding RNA molecules that target and regulate gene transcripts (Guo et al., 
2018), were found to be important in both the development and progression of colitis, 
particularly in terms of regulating inflammation, serving as disease biomarkers, and 
responding to therapies (Feng et al., 2018; Lopetuso et al., 2018; Minacapelli et al., 2019; 
Morilla et al., 2018; Schonauen et al., 2018; Singh et al., 2014a). The importance of miRs 
in regulating colitis was highlighted in our previous report showing that deficiency in 
only one miR (miR-155) was able to protect mice from developing severe colitis 
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symptoms by a reduction in the inflammatory T helper (Th) type responses (Singh et al., 
2014a). 
In the current report, we investigated the effectiveness of resveratrol treatment in 
another mouse model of chemically-induced colitis, using 2,4,6-Trinitrobenzenesulfonic 
acid solution (TNBS), which is known to activate inflammatory T cells. We found that 
resveratrol treatment attenuated severe disease development, resulting in a shift from a 
pro-inflammatory Th17 phenotype to a more anti-inflammatory T cell response 
characterized by increased regulatory T cells (Tregs) and those producing IL-10. 
Microarray analysis of miR profiles in T cells revealed several miRs (e.g. miR-31, Let-
7a, and miR-132) that target anti-inflammatory T cell factors were downregulated by 
resveratrol. In this study we further analyzed the role of miR-31, which was found to 
target Treg transcription factor FoxP3. These findings were even more interesting after 
analysis of human UC colitis patients revealed this patient population had significantly 
higher expression of miR-31 in disease-associated tissues. Altogether, the study 
highlights that miR-31 is a potential target for prevention of colitis and possibly CRC. 
4.3 MATERIALS AND METHODS 
Animals. Female mice (BALB/c) aged 8-10 weeks were obtained from Jackson 
Laboratories (Bar Harbor, ME) and housed at the University of South Carolina, School of 
Medicine (Columbia, SC) AAALAC-accredited animal facility. All mice were housed in 
specific pathogen (SPF) free conditions in rooms with controlled temperature, ventilation, 
and normal light/dark cycles. All procedures performed on mice followed National 
Institutes of Health (NIH) guidelines under protocols approved by the Institutional 
Animal Care and Use Committee (IACUC). 
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Induction of colitis and treatment with resveratrol. Colitis was induced in 
experimental mice as previously described (Elson et al., 1996). Briefly, TNBS purchased 
from Sigma-Aldrich (MO, USA) was administered by intrarectal injection using a 38 mm 
catheter into lightly anesthetized (5% isoflurane) at a concentration of 1 mg TNBS 
dissolved in 0.1 ml of ethanol (50%). Mice were keep upright for 30 seconds following 
injection to ensure proper dispersion of the chemical into the colon area. Vehicle control 
mice were given an injection of 0.1 ml of ethanol (50%) without TNBS to negate any 
inflammatory or adverse effects caused by the alcohol. Resveratrol, purchased from 
Sigma-Aldrich, was given 24 hours prior to TNBS injection and given daily until 
completion of the experiment (5 days) by using a 30 mm oral gavage needle at a dose of 
100 mg/kg in 0.1ml of vehicle (1% carboxymethyl cellulose, CMC). In the current study, 
the following experimental groups were used:  Control mice (Vehicle) were given 50% 
ethanol intrarectal administration and daily oral gavage of vehicle (1% CMC); Naïve 
mice given treatment (Resveratrol) were given intrarectal administration of 50% ethanol 
and daily oral gavage of 100 mg/kg of the resveratrol. Disease controls (TNBS+Veh) 
were given 1mg intrarectal administration of TNBS and daily oral gavage of vehicle (1% 
CMC). Treatment groups (TNBS+Res) were given 1mg intrarectal administration of 
TNBS and daily oral gavage of resveratrol (100 mg/kg). 
Assessment of disease parameters. To assess disease, experimental mice were 
weighed daily through the entirety of the experiment (5-6 days). Colonoscopies were 
performed to evaluate extent of damage (ulcerations and bleeding) to the colons prior to 
the end of the experiment (day 3). At the study endpoint, mice were euthanized by 
overdose of isoflurane. Excised colons were measured for length and proximal colons 
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sections (1cm) were collected for histology. 10% formalin fixed tissues were stained with 
hematoxylin and eosin (H&E) to assess colonic damage caused by TNBS administration. 
To assess T cell response to disease and treatment, flow cytometry was performed on 
single cell suspensions isolated from MLNs and stained using antibodies for the 
following T cell and T cell subsets: overall T cells (CD3+), T helper cells (CD4+), 
cytotoxic T cells (CD8+), Tregs (CD4+FoxP3+), IL-10 producing cells (CD4+IL-10+), 
Th17 cells (CD4+IL-17+), and Th1 cells (CD4+IFNγ+). All antibodies used in these 
studies were purchased from BioLegend (CA, USA). For transcription factor staining, 
True-Nuclear Transcription Factor Buffer set from BioLegend was used as per 
instructions from the manufacturer. 
Analysis of miRNA. MicroRNA arrays were performed on RNA isolated from 
cells collected from the MLN of experimental mice as previously described (Miranda et 
al., 2018). Each sample consisted of a pool of 5 biological replicates. For each miRNA 
microarray, FlashTag Biotin HSR RNA Labeling kit from Affymetrix (Thermo Fisher 
Scientific, MA, USA) was used and tagged samples were later hybridized to the 
Affymetrix miRNA 4.0 chip. Chips were scanned with an Affymetrix GCS 3000 system. 
For transcriptome microarrays, 100ng total RNA was used as starting material. RNA was 
prepared for hybridization by using the Affymetrix GeneChip WT PLUS Reagent Kit 
according to protocol from the manufacturer. Affymetrix Expression Console Version 
software was used to evaluate quality control of the samples, as well as initial analysis of 
the microarray data to include principal component analysis, heatmaps depicting raw 
signal expression, log2 fold change (FC) calculations, and direct comparisons among the 
experimental groups. Ingenuity Pathway Analysis (IPA, http://www.ingenuity.com/) was 
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used to generate miRNA-gene target pathways based on differentially regulated miRNA 
profiles, which was determined to be a greater than ±2 log2 fold change between two 
different experimental groups. miR validation studies were performed by first preparing 
complimentary DNA (cDNA) from isolated RNA samples using the miScript II RT kit 
(Qiagen, MD, USA) followed by quantitative real time PCR (qRT-PCR) using a CFX 
Connect Real Time System (Bio-Rad, PA, USA). PCR reactions were performed using 
mouse-specific miR primers purchased from Qiagen. Primers included mmu-miR-31-5p 
(MI0000579), mmu-Let-7a (MIMAT0004620), and mmu-miR-132-3p 
(MIMAT0000144). Expression levels were normalized to Snord96a (MS00033733) 
levels. Fold changes were calculated using the 2−ΔΔCT method. 
Transfection experiments with miR-31-5p mimic or inhibitor and target gene 
quantification. Transfection experiments were carried out as previously described 
(Alghetaa et al., 2018; Busbee et al., 2015). Excised MLNs from naïve BALB/c were 
prepared in a single cell suspension before culturing in complete RPMI 1640 media 
supplemented with heat inactivated 10% fetal bovine serum, 10mM L-glutamine, 10mM 
HEPES, 50µM β-mercaptoethanol, and 100µg/ml penicillin/streptomycin. MLN cells 
were seeded (2 x 105 cells per well) in a 24-well plate and activated with 1 µg/ml of 
bacterial toxin staphylococcal enterotoxin B (SEB) purchased from Toxin Technologies 
Inc. (FL, USA). Cells were then transfected with either 20nM of synthetic mmu-miR-31–
5p mimic (AGGCAAGAUGCUGGCAUAGCUG) or anti-mmu-miR-31–5p 
(AGGCAAGAUGCUGGCAUAGCUG) using HiPerfect Transfection Reagent from 
Qiagen for 24 hours. Expression levels for miR-31 and transcriptional factor FoxP3 
(forward: CCCATCCCCAGGAGTCTTG; reverse: ACCATGACTAGGGGCACTGTA) 
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were determined using qRT-PCR. For FoxP3, expression levels were normalized to β 
actin (forward: GGCTGTATTCCCCTCCG; reverse: 
CCAGTTGGTAACAATGCCATGT). 
Dataset for human colitis patient population. Data on human miR-31 
expression levels was obtained from the National Center for Biotechnology Information 
(NCBI) Gene Expression Omnibus (GEO) repository. The human dataset used was GEO 
accession GSE68306 provided by Huang et al. and published elsewhere (Pekow et al., 
2017). The data set consisted of colon tissue biopsies from normal healthy controls 
(n=16) and ulcerative colitis (UC) patients (n=29). For UC patients, samples consisted of 
three distinct tissue biopsy types: UC associated with neoplastic tissues (n=11), UC 
patients without neoplasia (n=9), and non-dysplastic UC mucosa adjacent to a neoplastic 
lesion (n=9). For the current report, analysis was performed using two different 
comparisons. First, expression of miR-31 in healthy tissue samples (n=16) was compared 
to UC patients (n=29). Second, miR-31 expression from healthy controls (n=16) was 
compared to colonic tissues from UC patients associated with neoplasia (n=11). Raw 
expression values were obtained from the provided online dataset and based on 
NanoString nCounter v1.7.0 platform performed on RNA isolated from formalin-fixed 
paraffin embedded tissue samples. 
Statistical Analysis. GraphPad Prism software (CA, USA) was used for most of 
the statistical analysis depicted in the current report unless otherwise noted. For in vivo 
colitis experiments, at least 5 mice were used per experimental group. For in vitro assays, 
all experiments were performed in triplicate. For statistical differences, significance (p 
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value of ≤ 0.05) was determined using one-way ANOVA followed by Tukey’s post-hoc 
multiple comparisons test unless otherwise stated. 
4.4 RESULTS 
Treatment with resveratrol reduces severity of TNBS-induced colitis 
In the current study, we investigated the efficiency of resveratrol to prevent a 
chemically-induced murine colitis model using TNBS. To investigate prevention of 
disease by this natural compound, treatment groups were given resveratrol 24 hours prior 
to induction of disease by TNBS, followed by daily oral administrations of the treatment. 
As shown, colitis mice (TNBS+Veh) had significant weight loss (~15%) during the 
course of the study compared to control groups (Vehicle or Resveratrol), but colitis mice 
pre-treated with resveratrol (TNBS+Res) had significantly decreased incidence of weight 
loss (Fig. 1A-B). Another hallmark of many colitis models is the shortening of the colon 
after disease induction. The colons from TNBS mice were significantly shorter while 
TNBS+Res mice had similar colon lengths when compared to controls (Fig. 1C-D). 
Colonoscopies performed during the peak of disease (day 3) revealed that while TNBS 
mice had typical disease-associated features such as ulcerations and bleeding compared 
to normal colons, colons of TNBS+Res mice had reduced presence of these classical 
clinical parameters (Fig. 1E). Histological evaluation corroborated with these 
observations from colonoscopies as there were significant signs of tissue damage (e.g. 
cellular infiltration, loss of normal colonic tissue architecture) in TNBS mouse colons 
compared to controls, and this damage was not present or reduced in colons from 
TNBS+Res mice (Fig. 1F). These observations together demonstrated that resveratrol 
treatment effectively prevented TNBS-induced colitis. 
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Treatment of TNBS-induced colitis mice with resveratrol results in a shift 
from a pro-inflammatory to anti-inflammatory T helper response in MLN 
To investigate if this effect of resveratrol was due to reduction in pro-
inflammatory T helper responses (IL-17) while inducing anti-inflammatory types (Tregs 
and IL-10 production), MLNs from the TNBS experimental groups were evaluated to 
determine T cell distribution during disease and treatment. The T cell subsets evaluated 
included all T cells (Fig. 2A), T helper and cytotoxic T cells (Fig. 2B), Tregs (Fig. 2C), 
IL-10 T helper cells (Fig. 2D), and Th17 cells (Fig. 2E). Based on percentages obtained 
from flow cytometry phenotyping (Figs. 2A-E), absolute cell numbers were assessed in 
MLNs from all experimental groups. Overall T cells (Fig. 3A), including CD4+ T helper 
(Fig. 3B) and CD8+ cytotoxic (Fig. 3C), were significantly increased in TNBS+Veh mice 
compared to the other experimental groups, and TNBS+Res mice reduced these subsets 
to the levels seen in normal controls. Despite an overall increase in CD4+ T cells, there 
was a decrease in the anti-inflammatory Treg (Fig. 3D) and IL-10-producing (Fig. 2E) 
cells during TNBS induction, while colitis mice treated with resveratrol had significantly 
higher numbers of these anti-inflammatory subsets compared to controls. A significant 
proportion of the CD4+ T cell subsets in TNBS+Veh mice appeared to be pro-
inflammatory Th17 cells (Fig. 3F), and treatment with resveratrol during the disease state 
showed ablation of the increase in this T cell subset, comparable to control levels. Taken 
altogether, treatment with resveratrol appeared to prevent colitis-associated increases in 
pro-inflammatory Th17 cells, likely through the induction of anti-inflammatory subsets 
such as Tregs and CD4+ IL-10-producing cells. 
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Resveratrol treatment downregulates miRs that target Treg transcription 
factor FoxP3 and other anti-inflammatory T cell-associated factors 
Next, we investigated if miRs regulated the anti-inflammatory properties of 
resveratrol.  To that end, we investigated the miR profile of cells from the MLN. 
Principal component analysis (PCA) from pooled samples from all experimental groups 
showed that the miR profiles of controls (Vehicle and Resveratrol) were most similar 
with opposite deviations occurring when compared to TNBS+Veh and TNBS+Res 
groups (Fig. 4A). Direct comparisons among two groups at a time, with the significance 
criteria set to a ±2-fold change, revealed the greatest difference was among the 
TNBS+Veh vs. TNBS+Res groups (Fig. 4B). Comparison of these two groups showed 
260 total miRs (out of 3195 probed) were significantly altered, with TNBS+Res 
downregulating 198 and upregulating 62 compared to TNBS+Veh (Fig. 4C). A heatmap 
showing raw expression of these 260 significantly altered miRs for all experimental 
groups is depicted in Fig. 3D. IPA analysis of these 260 significantly altered miRs 
revealed several were downregulated in the TNBS+Res group that targeted key anti-
inflammatory T cell components such as FoxP3 (miR-31-5p, miR-182-5p, miR-210-3p), 
IL-10 (miR-146-a-5p and miR-27a-5p), TGFβ2/3 (miR132-3p, miR-1999a-5p, miR193a-
3p, miR-148a-3p, let-7a-3p, miR-29b-3p), and several SMAD proteins (miR-330-5p, 
miR-139-3p, miR-30c-1-3p*, miR-16-5p*, miR-27a-3p) (Fig. 5). Among these miRs 
targeting key anti-inflammatory T cell factors, miR-31, predicted to target FoxP3, was 
the most significantly downregulated (-6.790 fold change) when comparing TNBS+Res 
vs TNBS+Veh groups (Fig. 5). Thus, the microarray data suggested that treatment with 
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resveratrol was able to downregulate miRs that normally targeted anti-inflammatory gene 
expression and components. 
Resveratrol downregulates FoxP3-targeting miR-31 which is highly 
upregulated in human colitis patients  
As miR-31 was the most significantly downregulated miR indicated in targeting 
anti-inflammatory T cell response and factors, PCR was performed to validate the 
microarray results. Results showed that miR-31 was significantly increased in the MLN 
of TNBS+Veh mice compared to the control groups, whereas TNBS mice treated with 
resveratrol had decreased expression of this miRNA (Fig. 6A). Validation was also 
performed on other miRs highlighted in Fig. 5 to include let-7a (Fig. 6B) and miR-132 
(Fig. 6C). As with miR-31, results showed these miRs were increased in the disease state 
(TNBS+Veh), but treatment with resveratrol (TNBS+Res) prevented their disease-
associated upregulation. Next, alignment analysis was performed to determine the 
potential of FoxP3 being a target. miR-31 was found to have three potential binding sites 
on the 3’-untranslated region (UTR) of the FoxP3 transcript, two of which had highly-
probable miR-target mRNA interactions as predicted by mirSVR and PhastCons scores 
(Fig. 6D). Transfection experiments were performed to determine if alterations in this 
miR affected FoxP3 expression by giving SEB-activated T cells from the MLN either 
mock (just transfection reagent), miR-31-mimic, or miR-31-inhibitor. PCR validation of 
miR-31 expression showed the transfection was successful (Fig. 6E), and the results 
indicated that when miR-31 was upregulated (miR-mimic), expression of FoxP3 
transcript was downregulated (Fig. 6F). On the contrary, if miR-31 was inhibited, as in 
the case of treatment with resveratrol, then FoxP3 expression was increased. Collectively, 
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these data showed that FoxP3 expression was altered by miR-31, a diseased-associated 
miR that resveratrol treatment prevented from becoming upregulated. Lastly, as the 
TNBS-induced model indicated FoxP3-targeting miR-31 was a potential target in this 
murine model of colitis, human studies looking at miR expression in colon biopsies of 
UC patients was investigated to determine any applicable correlation between this animal 
model and the human patient population. As shown, miR-31 was found to be 
significantly increased in patients with UC when compared to controls (Fig. 6G). 
Interestingly enough, this upregulation of miR-31 was found to be even more significant 
in UC colon biopsies that developed colon cancer-associated neoplastic lesions when 
compared to healthy controls (Fig. 6H). These data provided a link with observed miR-31 
upregulation in the mouse model of colitis and human UC patient population, which 
resveratrol was able to prevent, effectively inhibiting miR-31 from targeting anti-
inflammatory FoxP3-mediated response. 
4.5 DISCUSSION 
 Previous studies have shown resveratrol is capable of preventing or at least 
reducing symptoms associated with animal models of colitis by a variety of different 
mechanisms. For example, in our earliest reports in the DSS-induced model of colitis, we 
showed resveratrol upregulated silent mating type information regulation-1 (SIRT-1) and 
downregulating nuclear transcription factor-kappaB (NF-κB) in immune cells (Singh et 
al., 2010). In a more recent report by Zhang et al., researchers confirmed our results that 
resveratrol treatment in the DSS model upregulated SIRT-1 in addition to mechanistic 
target of rapamycin (mTOR), while also downregulating other pro-inflammatory factors 
(e.g. autophagy‑related 12, Beclin‑1, and microtubule‑associated protein light chain 3 II) 
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(Zhang et al., 2019). As in this report, Yao et al. showed resveratrol effectively regulated 
Treg/Th17 signaling during DSS-induced colitis via modulating hypoxia inducible factor 
(HIF)-1α/mammalian target of rapamycin (mTOR) signaling pathways (Yao et al., 2015). 
In another chemically-induced colitis model in rats using oxazolone, resveratrol treatment 
was shown to exert anti-inflammatory and pro-apoptotic properties by inhibiting 
myeloperoxidase (MPO) and sphingosine kinase 1 (SphK1) (Abdin, 2013). In fact, the 
success of resveratrol treatment in animal models of colitis translates even into the human 
patient population. A double-blinded, placebo-controlled pilot study in UC patients has 
shown that supplementation of 500mg/kg of resveratrol for 6 weeks appears to improve 
quality of life and partially reduce disease severity in this patient population, thought to 
be due to the ability of this natural product to reduce oxidative stress (Samsami-Kor et 
al., 2015; Samsamikor et al., 2016). In addition to the growing number of studies 
identifying resveratrol as a potential preventative and therapeutic against colitis and even 
CRC, there are a number of reports linking dysregulation in miRs possible mechanisms 
which drive disease development and progression. 
 As early as a decade ago, reports highlighted the differential expression of certain 
miRs in patients with colitis (UC and CD) and CRC (Ahmed et al., 2009; Takagi et al., 
2010; Wu et al., 2008). In one of the earliest animal model reports, Chen et al. identified 
miR-155 was altered in activated CD4+ cells from TNBS-induced colitis mice (Chen et 
al., 2010), which supported our previous report showing miR-155 deficient mice had 
protection against colitis induction (Singh et al., 2014a). Since these early reports, the 
role of miR dysregulation in colitis is becoming more established from both a potential 
diagnostic tool to areas of therapeutic intervention. For example, a recent published 
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report suggest that serum levels of miR-146-5p are a better diagnostic tool to evaluate UC 
and CD severity than the standard C-reactive protein levels (Chen et al., 2019). miR-449a 
was suggested to be a possible predictor of colitis-associated CRC progression (Feng et 
al., 2018). Going beyond just diagnostic and biomarkers of disease, miRs are being 
looked as potential promoters and inhibitors of colitis as well. miR-590-5p, via inhibition 
of Yes-associated protein 1 (YAP), was shown to reduce intestinal inflammation in both 
colon cancer cells and mouse models of colitis with significant correlations in intestinal 
tissues from CD patients (Yu et al., 2018). An antagomir for miR-148a was reported to be 
a potentially effective drug treatment in amelioration of colitis because of its ability to 
selectively deplete the pro-inflammatory Th1 response without interrupting other 
protective immunological function during chronic colitis (Maschmeyer et al., 2018). The 
current report advances previous studies on miRs by demonstrating that miR-31 is a 
potential therapeutic target in colitis and CRC prevention. 
 The current study identifies the miR-31/FoxP3 axis as a means to prevent colitis 
development, showing this miR was significantly upregulated in the TNBS-induced 
murine model of colitis as well as documented in a dataset of UC colitis patients. In 2011, 
researchers reported that miR-31 was found to be highly dysregulated in epithelial cells 
from chronically inflamed mouse colons and APC(Min/+) tumors (Necela et al., 2011), 
and in that same year a report described how miR-31 increase correlated with chronic 
inflammation in IBD developing into neoplasia (Olaru et al., 2011). However, while 
many reports identify miR-31 as being abnormally high in colitis patients and animal 
models of colitis, the exact role of this miR in disease progression and development is 
somewhat controversial.   
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 Liu et al. found that colon epithelial-specific deletion of miR-31 resulted in a more severe 
form of colitis-associated colorectal cancer than wild-type counterparts (Liu et al., 2017), 
and another report suggested that overexpression of miR-31 in UC targeted and regulated 
the pro-inflammatory IL-13 signaling (Gwiggner et al., 2018). These reports align with 
other studies suggesting miR-31 is important in protecting against colitis by way of 
engaging mucosal healing processes during inflammatory events within the colon (Tian 
et al., 2019; Whiteoak et al., 2018). It is important to note that such findings do not 
necessarily contradict our data suggesting resveratrol-mediated targeting of miR-31 
assists in prevention of colitis. Such reports indicated miR-31 seemed to be protective in 
epithelial cells, whereas our report shows that in CD4+ immune cells, downregulating 
miR-31 helps initiate a potential anti-inflammatory Treg response. Thus, while 
upregulation of miR-31 in colonic epithelial cells might serve a protective role, in 
immune cells it has the potential to promote inflammation by reducing Treg 
development. This highlights the need to better understand through additional research 
how regulating miRs in different cell types might have varying consequences. 
Nevertheless, the current study provides evidence for additional pathways through which 
resveratrol offers a highly valuable preventative and therapeutic properties against colitis 




Figure 4.1 Treatment with resveratrol reduces clinical parameters in TNBS-induced 
colitis.  BALB/c mice were injected intrarectally with 1mg of TNBS to induce colitis. 
Mice treated with resveratrol were given 100mg/kg in vehicle (1% CMC) by oral gavage 
24 hours prior to the TNBS injection as well as daily up until the experimental end point 
(day 4). Experimental groups consisted of: Vehicle (n=5), Resveratrol (n=5), TNBS+Veh 
(n=5), and TNBS+Res (n=5). Initial clinical parameters consisted of evaluating weight 
(A), percent weight loss (B) and colon length (C-D). (E) Representative colonoscopies 
are shown from experimental groups during peak of disease (day 3). (F) Representative 
colon sections from fixed and paraffin-embedded tissue sections stained with H&E at 20x 
objective. Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was 
determined by using one-way ANOVA and post-hoc Tukey’s test for bar graphs and 





Figure 4.2 Treatment with resveratrol alters T cell subsets in the MLN of TNBS-
induced mice. TNBS disease and treatment with resveratrol were performed as described 
in Figure 4.1 legend. MLNs were excised from experimental groups (n=5 per 
experimental group), stained with T cell-specific antibodies, and analyzed by flow 
cytometry. Representative T cell subset staining by flow cytometry was as follows: (A) 
CD3+ positive histogram plot; (B) CD4+ and CD8+ dot plot; (C) CD4+-gated FoxP3+ 




Figure 4.3 Treatment with resveratrol increases absolute cell numbers of anti-
inflammatory T cell subsets in the MLN of TNBS-induced mice. TNBS disease and 
treatment with resveratrol were performed as described in Figure 4.1 legend. MLNs were 
excised from experimental groups (n=5 per experimental group), stained with T cell-
specific antibodies, and analyzed by flow cytometry (as represented in Figure 4.2). Bar 
graphs depict absolute cell numbers in MLN for all T cells (F), T helper cells (G), 
cytotoxic T cells ( H), Tregs (I), T helper producing IL-10 cells (J), and Th17  cells (K). 
Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was determined by 
using one-way ANOVA and post-hoc Tukey’s test for bar dot graphs. Data are 























Figure 4.4 Treatment with resveratrol alters the miR profile in TNBS-induced 
colitis MLN.  TNBS disease and treatment with resveratrol were performed as described 
in Figure 4.1 legend. RNA from MLN of experimental groups was isolated for miR 
microarray analysis using the murine-specific Affymetrix miRNA 4.0 chip. Experimental 
groups (Vehicle, Resveratrol, TNBS+Veh, and TNBS+Res) consisted of pools of 5 mice 
per group. Affymetrix Expression Console Version software was used to generate the 
following comparisons: (A) 3D PCA plot comparing all experimental groups; (B) 
multiple bar graph comparisons depicting significantly altered upregulated and 
downregulated (± 2 fold change) miRs between two experimental groups; (C) scatter plot 
depicting 260 significantly upregulated (red dots) and downregulated (green dots) miRs 
out of 3195 total between TNBS+Res and TNBS+Veh; and (D) heat map depicting raw 










Figure 4.5 Treatment with resveratrol results in downregulation of several miRs 
that target anti-inflammatory T cell-associated factors.  TNBS disease and treatment 
with resveratrol were performed as described in Figure 4.1 legend. 260 significantly 
altered miRs between TNBS+Res vs. TNBS+Veh noted in Figure 4.3 legend were 
subjected to Ingenuity Pathway Analysis (IPA). Depicted is an IPA-generated interaction 
chart showing significantly altered miRs targeting factors associated with anti-
inflammatory T cell responses. Green colors represent downregulated miRs and Red 
colors represent upregulated miRs. The calculated fold changes between TNBS+Res and 
TNBS+Veh groups are depicted below each included miR.  Purple arrows indicate 
predicted, highly predicted, and experimentally-proven interactions of the miR with 













Figure 4.6 Resveratrol prevents FoxP3-targeting miR-31 upregulation in TNBS-
induced colitis which correlates with miR-31 upregulation in human UC patients.  
TNBS disease and treatment with resveratrol were performed as described in Figure 4.1 
legend. RNA was isolated from MLN of Vehicle (n=5), Resveratrol (n=5), TNBS+Veh 
(n=5), and TNBS+Res (n=5) to validate expression levels of miR-31 (A), Let-7a (B), and 
miR-132 (C). (D) Predicted miR-31 and FoxP3 alignment sites (with mirSVR and 
Phastcon scores) were obtained from microrna.org. For transfection experiments, single-
cell suspensions from normal mouse MLN were seeded (1x105 cells per well) and 
activated with SEB (1µg/ml) for 24 hours before collecting total RNA from groups. 
Experimental groups consisted of transfection reagent only mock (n=5), miR-31 mimic 
(n=5), and miR-31 inhibitor (n=5). Depicted are PCR-generated expression fold changes 
for miR-31 (E) and FoxP3 (F). For human samples depicted, raw expression values of 
miR-31 from colonic biopsies were obtained from GEO data GSE68306. Two 
comparisons are depicted: (G) Normal Healthy controls (n=16) vs. all UC patients 
(n=29); and (H) Normal Healthy controls (n=16) vs. UC patients associated with 
neoplasia (n=11).  Significance (p-value: *<0.05, **<0.01, ***<0.005, ****<0.001) was 
determined by using one-way ANOVA and post-hoc Tukey’s test for bar dot graphs 
when comparing three or more groups. Data are representative of at least 3 independent 
experiments. For human datasets, significance was determined using an unpaired, two-






Resveratrol, a natural polyphenol found in various food and beverage products 
such as grapes, peanuts, and wine, is a potent anti-inflammatory agent capable of 
preventing or reducing symptoms associated with colitis and colitis-induced CRC by a 
variety of mechanisms. Using well-established murine models of both colitis (TNBS) and 
CRC (AOM/DSS), results showed that resveratrol was able to prevent or greatly reduce 
the symptoms associated with these animal models, which is supported by previously 
published reports. Highlighted in this disseration is the ability of resveratrol to regulate 
the gut microbiome and induce epigenetic modifications (e.g. miRs and HDACs) to 
promote induction of anti-inflammatory T cell subset, Tregs (CD4+FoxP3+).  
In the microbiome, resveratrol promotes a microenvironment with increased 
production of SCFA butyrate, a suppressor of HDACS capable of inducing Tregs. In both 
the colitis model and CRC model, resveratrol was shown to alter the gut microbiome to 
favor butyrate production. In particular, in both disease models resveratrol decreased 
Bacteriodes acidifaciens and enriched Akkermansia muciniphilia and Ruminococcus 
gnavus species. Fecal transfer experiments provided evidence that the resveratrol-altered 
microbiome was directly responsible for the anti-inflammatory immune response and 
subsequent protection against colitis and CRC, a new and exiting finding not previously 
known. Interestingly, in addition to suppression of HDACs by increased butyrate 
production, resveratrol was shown to be able to suppress a majority of HDACs 
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independently of butyrate, and this directly correlated with increased Treg induction. In 
addition to alterations in  the microbiome leading to Treg-promoting HDAC suppression, 
resveratrol is capable of downregulating several miRs (miR-31, let-7a, and miR-132) that 
target Treg-related factors (FoxP3, SMAD proteins, STATs, and TGF-β). Transfection 
experiments confirmed that miR-31 downregulation by resveratrol increased Treg-related 
transcription factor FoxP3, which was a signficant finding considering that UC patients 
were shown to have increased expression of this particular miR.   
These new findings and mechanisms by which resveratrol regulates inflammation, 
which has the potential to promote cancer, provide additional evidence to suggest this 
natural compound can be a beneficial therapeutic or preventative measure against colitis 
and colitis associated CRC by way of induction of Tregs. The ability of resveratrol to 
induce Tregs is important not only because this T cell subset has anti-inflammatory 
properties, but also data presented here shows that increased Tregs correlate with 
increased survival of CRC patients. Inasmuch, the data and results presented here 
promote a strong case for this natural compound to be used as a safe alternative to treat 
and prevent colitis and CRC. 
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